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KINETIC VASCULOGENIC ANALYSES OF ENDOTHELIAL COLONY FORMING 
CELLS EXPOSED TO INTRAUTERINE DIABETES 
  
Vasculogenesis is a complex process by which endothelial stem and progenitor cells 
undergo de novo vessel formation. Quantitative assessment of vasculogenesis is a central 
readout of endothelial progenitor cell functionality.  However, current assays lack kinetic 
measurements.  To address this issue, new approaches were developed to quantitatively 
assess in vitro endothelial colony forming cell (ECFC) network formation in real 
time.  Eight parameters of network structure were quantified using novel Kinetic Analysis 
of Vasculogenesis (KAV) software.  KAV assessment of structure complexity identified 
two phases of network formation.  This observation guided the development of additional 
vasculogenic readouts, including a tissue cytometry approach to quantify the frequency 
and localization of dividing ECFCs within cell networks.  Additionally, FIJI TrackMate was 
used to quantify ECFC displacement and speed at the single cell level during network 
formation.  These novel approaches were then applied to determine how intrauterine 
exposure to maternal type 2 diabetes mellitus (T2DM) impairs fetal ECFC vasculogenesis, 
and whether increased Transgelin 1 (TAGLN) expression in ECFCs from pregnancies 
complicated by gestational diabetes (GDM) was sufficient to impair vasculogenesis.  Fetal 
ECFCs exposed to maternal T2DM formed fewer initial network structures, which were 
not stable over time.  Correlation analyses identified that ECFC samples with greater 
division in branches formed fewer closed network structures and that reductions in ECFC 
movement decreased structural connectivity.  To identify specific cellular mechanisms and 
signaling pathways altered in ECFCs following intrauterine GDM exposure, these new 
techniques were also applied in TAGLN expression studies.  Similarly, ECFCs from GDM 
   ix 
pregnancies and ECFCs overexpressing TAGLN exhibited impaired vasculogenesis and 
decreased migration.  Both ECFCs from GDM pregnancies as well as ECFCs over-
expressing TAGLN exhibited increased phosphorylation of myosin light chain.  Reduction 
of myosin light chain phosphorylation via Rho kinase inhibition increased ECFC migration; 
therefore, increased TAGLN was sufficient to impair ECFC vasculogenic function.  Overall, 
identification of these novel phenotypes provides evidence for the molecular mechanisms 
contributing to aberrant ECFC vasculogenesis.  Determining how intrauterine exposure to 
maternal T2DM and GDM alters fetal ECFC function will enable greater understanding of 
the chronic vascular pathologies observed in children from pregnancies complicated by 
diabetes mellitus. 
         Laura S. Haneline, M.D., Chair 
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CHAPTER 1: INTRODUCTION  
   2 
 
Vasculogenesis 
Vasculogenesis is the dynamic process by which angioblasts in the developing embryo 
differentiate into endothelial cells and form new vessels in the absence of preexisting 
vascular structures [1].  Following vasculogenesis, the process of angiogenesis occurs, 
which involves the expansion of the pre-existing vascular network.  Finally, angiogenesis 
is followed by arteriogenesis, a process where pericytes and vascular smooth muscle cells 
cover the endothelial vessels to provide stability and modulate vessel perfusion.  
Vasculogenesis can, therefore, be differentiated from these other modes of vessel 
formation, as outlined by Carmeliet and Jain (Figure 1) [2].  The establishment of the 
vascular network is a complex process regulated at several different stages by 
coordinated molecular mechanisms.  Two of the key signaling pathways regulating 
endothelial cell vasculogenesis are the Notch and vascular endothelial growth factor 
(VEGF) pathways [3]. 
 
Notch signaling is implicated in cell fate determination and differentiation in numerous 
physiologic processes including limb development, neurogenesis, arterio-venous 
specification, and vasculogenesis [4,5].  In the vasculature, Notch signaling regulates the 
dynamic selection of endothelial tip cells, which guide the process of angiogenesis [6].  
Four Notch receptors have been identified (NOTCH 1-4) as well as five ligands [JAGGED 
1-2 and Delta-like ligand 1, 3, 4 (DLL1, DLL3, DLL4)].  In the endothelium, vascular 
endothelial growth factor A (VEGF-A) signaling through vascular endothelial growth factor 
receptor 2 (VEGFR2) up-regulates expression of DLL4 (Figure 2) [7].  Increasing the DLL4 
ligand leads to subsequent activation of Notch signaling through binding to NOTCH1 or 
NOTCH4 on adjacent “stalk” cells. Activation of Notch signaling in adjacent cells restricts 
tip cell formation, allowing for appropriate tip to stalk cell ratio, which promotes effective 
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branching [8].  Following Notch receptor activation, the Notch intracellular domain is 
cleaved by the gamma secretase/presenilin complex and A Disintegrin and 
Metalloproteinase family proteases [9,10].  The Notch intracellular domain subsequently 
translocates to the nucleus where it interacts with the CBF1/Su(H)/Lag-1 transcription 
factor complex and regulates expression of genes such as MYC, p21, HESR1, and the 
Hairy/Enhancer of Split gene family [11].  Downstream Notch effector proteins then act as 
a feedback loop to modulate VEGF receptor expression.  For example, HESR1 decreases 
VEGFR2 expression in endothelial cells [11].  In addition, the “stalk” cells adjacent to 
DLL4-expressing cells, undergo NOTCH1-mediated upregulation of vascular endothelial 
receptor 1 (VEGFR1), also known as Flt-1, and JAGGED1 [12–14].  VEGFR1 is a receptor 
with high affinity but low activity and acts primarily as a competitive inhibitor of VEGF 
signaling [13].  Importantly, VEGF signaling occurs in both tip and stalk cells but is thought 
to induce migration in tip cells, while causing proliferation in stalk cells [15].  Overall, Notch 
and VEGF signaling are critical to endothelial sprouting in angiogenesis. 
 
In addition to modulating endothelial sprouting, Notch and VEGF are key regulators of cell 
fate determination.  In endothelial progenitor cells (EPCs), Notch signaling is a primary 
mediator of the negative feedback loop that links VEGF activation with maturation to fully 
differentiated endothelial cells [16].  These signaling pathways aren’t just important in 
developmental vasculogenesis.  Recent studies suggest that some progenitor cells are 
also capable of undergoing ‘postnatal vasculogenesis’.  Establishment of neo-vasculature 
postnatally is an important mechanism for vascular homeostasis and for new vessel 
formation in response to disease [17].  Therefore, EPCs not only undergo de novo vessel 
formation to establish embryonic vasculature during development, but they also participate 
in postnatal vasculogenesis. Investigation is ongoing to understand EPC function during 
vascular development as well as their potential therapeutic use for postnatal vascular 
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repair [18–22].  The goals of this work are to identify the molecular mechanisms underlying 
endothelial colony forming cell vasculogenesis, and to determine how intrauterine 
exposure to maternal diabetes mellitus disrupts these processes and alters endothelial 
colony forming cell function. 
 
Endothelial Colony Forming Cells 
In 1997, Asahara et al. first reported that circulating EPCs incorporate into active sites of 
angiogenesis.  In addition, Asahara et al. were the first to suggest EPCs for use in 
angiogenic therapies to augment vessel growth in ischemic tissues and to deliver 
angiogenic regulatory agents [23].  Since that initial report, many attempts have been 
made to define and characterize EPC populations [24–27].  Currently, the term, 
‘endothelial progenitor cell,’ describes a diverse collection of cell types defined by 
clonogenic potential and cell surface markers such as CD133, KDR, VE-cadherin, and 
CD34 [28–30]. 
 
One EPC subset, endothelial colony forming cells (ECFCs), is a well-defined cell 
population that displays key characteristics of an immature EPC.  These characteristics 
include high proliferative potential, self-renewal capacity, and de novo vessel formation in 
vivo [17,31,32].  ECFCs reside in endothelium to maintain vascular integrity and circulate 
in the peripheral blood to facilitate vessel formation or repair [17,33–35].  Moreover, 
ECFCs are enriched in umbilical cord blood, a non-invasive source for cell acquisition with 
therapeutic potential [36].  ECFC cord-blood enrichment occurs at 33-36 weeks 
gestational age and is maintained through the term of the pregnancy [37].  Importantly, 
umbilical cord blood-derived ECFCs are fetal cells.  Thus, initial studies to characterize 
cord-blood-derived ECFCs focused on functional comparisons with ECFCs isolated from 
adult peripheral blood [38]. 
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In 2004, a hierarchy of endothelial stem and progenitor cells in adult and umbilical cord 
blood was identified based on clonogenic and proliferative potential [31].  The hierarchy 
includes high proliferative potential ECFCs (HPP-ECFCs), low proliferative potential 
ECFCs (LPP-ECFCs), endothelial cell clusters, and fully differentiated endothelial cells 
(ECs) (Figure 3).  HPP-ECFCs are defined not only by their ability to form large colonies 
upon initial plating, but also the ability to form secondary and tertiary colonies upon re-
plating.  Importantly, colonies produced by HPP-ECFCs include all other differentiated cell 
stages of the hierarchy (LPPs, cell clusters, and ECs).  Interestingly, umbilical cord-blood 
contains a higher frequency of ECFCs with robust clonal proliferative potential compared 
to adult peripheral blood [31,36].  In two week, single cell colony formation assays, cord 
blood-derived ECFCs form significantly more HPP-ECFC colonies (2000+ cells) and fewer 
cell cluster colonies (2-50 cells) compared to adult peripheral blood-derived ECFCs [31].  
During 60 days of culture, cord blood-derived ECFCs undergo approximately 40 
cumulative population doublings compared to adult peripheral blood-derived ECFCs, 
which achieve about half as many [31].  Therefore, the population doubling time for cord-
blood-derived ECFCs is approximately 1.5 days compared to nearly 4 days for adult 
peripheral blood ECFCs.  Thus, cord blood-derived ECFCs have greater therapeutic 
potential since the acquisition of sufficient cell numbers affects ECFC efficacy in 
regenerative medicine applications [39]. 
 
Despite differences in clonogenic and proliferative potential, ECFCs isolated from adult 
peripheral blood and umbilical cord blood have similar surface marker expression, 
including CD31, CD141, CD105, CD146, CD144, von Willebrand factor, and Flk-1 [31].  
Neither population contains cells that express the lymphocyte markers CD45 or CD14.  
Interestingly, both populations contain a subset of cells expressing hematopoietic 
progenitor markers such as CD34, CD133, and CD117.  However, the implications of 
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differential progenitor surface expression remain unclear.  Based on these results, cord 
blood and adult peripheral blood-derived ECFCs exhibit similar endothelial and 
hematopoietic surface marker expression patterns.  The common surface markers 
analyzed in these studies, however are not sufficient to discern proliferative differences 
identified in population doubling assays.  Therefore, the implications of differential surface 
marker expression on ECFC clonogenicity are yet to be elucidated.  Overall, the 
clonogenic hierarchy assay is an important measure of individual cell clonogenic potential 
and of cell differentiation content in an entire ECFC sample.  Importantly, the hierarchy 
assay is considered a gold standard assessment in the field and can be applied to identify 
how ECFC samples are altered in different pathologic states. 
 
Assessments of ECFC Function: Modeling Vasculogenesis 
In addition to their high clonogenicity, ECFCs are capable of de novo vessel formation in 
vivo, making them an attractive cell source for engineered blood vessel models  [36,40–
42].  Modeling vasculogenesis by seeding cells in extracellular matrix is a standard 
quantitative measurement to assess cell function both  in vitro and in vivo [43,44].  In 
addition, modeling provides an opportunity to identify the impact of fundamental 
properties, such as the physical properties of the extracellular matrix, on the process of 
vessel formation.  Since ECFCs have been explored extensively for use in regenerative 
vascular therapies, optimized conditions have been established to enhance ECFC 
vasculogenesis in 3D matrices [40].  Specifically, increasing collagen concentration in gel 
matrices decreases the number of ECFC-derived vessels, but increases average vessel 
size following implantation in vivo.  Optimization of transplant matrices will improve ECFC 
transplant efficacy in vivo. 
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Blood vessels formed by ECFCs exhibit normal blood flow, are selectively permeable to 
macromolecules, and are capable of leukocyte-endothelial interactions in response to 
cytokine activation [45].  Not surprisingly, the ability of ECFCs to form neo-vasculature 
following implantation is dependent on the tissue source from which they are derived.  In 
a vasculogenesis model where ECFCs were embedded in collagen gels with 10T1/2 
(mouse embryonic fibroblast) cells and transplanted into severe combined 
immunodeficient mice, adult peripheral blood-derived ECFCs formed blood vessels four 
days after transplantation with perfusion occurring around 11 days post-transplant [45].  
However, the vessels formed by the adult ECFCs were unstable and were almost 
completely gone 21 days after transplantation.  In contrast, cord-blood derived ECFCs 
formed dense vessel networks that were stable in vivo for more than 120 days [45].  
Therefore, it is evident that not all ECFCs populations have the same functional 
capabilities, and that cord-blood-derived ECFCs may be more efficacious for therapeutic 
use. 
 
The outcomes from ECFC functional assessments are similar to previous studies 
examining hematopoietic stem progenitor cells.  Similar to ECFCs, hematopoietic 
progenitor cells are enriched in umbilical cord blood compared to bone marrow [46].  
Hematopoietic progenitor cell division also creates a hierarchy, such that population 
subsets can be discerned based on proliferation and differentiation capabilities [47,48].  
Moreover, cord blood-derived hematopoietic progenitor cells exhibit enhanced 
proliferative capacity and re-plating, or self-renewal capacity, in vitro [46,47,49–51].  Thus, 
ECFC enrichment and functional capabilities closely mirror previously established 
characteristics of hematopoietic progenitor cells. 
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Fetal Origins of Adult Disease 
In 1989, the fetal origins of adult disease (FOAD) hypothesis was first proposed by Dr. 
David Barker in the Lancet [52].  His proposition, which was supported by strong 
epidemiologic data, was that environmental influences impairing growth and development 
early in life could be risk factors for ischemic heart disease later in life.  The basic premise 
of Dr. Barker’s initial assertion is still maintained today in the current FOAD hypothesis, 
which states that events transpiring during early development significantly impact the risk 
for developing multiple diseases later in life [53].  However, since Dr. Barker’s initial 
assertion, the FOAD hypothesis has been expanded to include additional morbidities, 
such that low birth weight is now associated with coronary artery disease, hypertension, 
obesity, and insulin resistance [53–55]. 
 
Low birth weight, resulting from abnormal developmental environments, is not the only 
clinical measure associated with long-term health outcomes.  Acute and chronic 
morbidities resulting from exposure to maternal diabetes mellitus during development 
have also been associated with poor health outcomes in children.  Type 2 diabetes 
mellitus (T2DM) occurs when the body is not able to use insulin produced by the pancreas 
to lower blood glucose, resulting in subsequent development of hyperglycemia [56].  
Maternal glucose can consequently cross the placenta, leading to fetal exposure to 
hyperglycemia during development [57].  Importantly, clinical diagnosis of maternal 
hyperglycemia during pregnancy is classified into two subgroups depending on the timing 
of diagnosis.  Pre-gestational diabetes, most commonly T2DM, is defined as maternal 
hyperglycemia diagnosed prior to pregnancy.  Alternatively, the diagnosis of gestational 
diabetes mellitus (GDM) is defined as diabetes first diagnosed during pregnancy.  
Although GDM is most often diagnosed in the third trimester, the duration and severity of 
the glucose intolerance can vary.  Therefore, different treatment strategies are 
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implemented to maintain blood glucose levels.  Specifically, GDM may be conservatively 
managed by alterations in diet and exercise.  Alternately, GDM may require pharmacologic 
treatment to maintain normal glucose levels.  Typically, women receiving insulin therapy 
have more severe hyperglycemia, and/or are unable to manage glucose levels with diet 
and exercise.  Access to clinical information, including treatment strategies utilized during 
gestation, enables further differentiation of GDM samples during functional analysis. 
 
Early studies of the Pima Native Americans were the first to identify that fetal exposure to 
maternal T2DM enhances the risk of an offspring to develop T2DM during childhood [58–
63].  The Pima are an especially informative population to study because they have the 
highest reported prevalence of T2DM in the world [58].  The high prevalence in T2DM in 
this population is due to abrupt diet and lifestyle changes following infringement on Native 
American reservations during settlement of, what is today, Arizona in 1859.  In addition to 
high prevalence, the onset of T2DM in this population occurs early, at approximately 5-10 
years of age.  Due to the combination of high prevalence and early onset, a large 
percentage of women in the tribe develop diabetes prior to childbearing years.  This 
population, therefore, offers a unique opportunity to understand how maternal T2DM 
impacts fetal development. 
 
In the Pima tribe, children born to mothers with T2DM have a higher prevalence of the 
disease in early adulthood compared to children of non-diabetic mothers [62].  Moreover, 
intrauterine exposure to maternal diabetes results in higher systolic blood pressure and 
hemoglobin A1c in childhood [61,62].  Importantly, the observation that maternal T2DM 
impacts child health outcomes is not limited to the Pima population.  Similar findings have 
been confirmed in populations outside of the Pima tribe as well [64–68]. In non-Pima 
populations, maternal obesity and T2DM during pregnancy alters offspring weight, glucose 
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tolerance, and blood pressure [64].  Specifically, maternal T2DM exposure in utero 
increases body mass index in late childhood, which correlates with a long-standing risk of 
developing obesity [65,68].  Therefore, individuals exposed to T2DM in utero are at an 
increased risk for developing chronic diseases, such as high blood pressure, later in life. 
 
Increasing Pregnancies are Complicated by Maternal Diabetes Mellitus 
Widespread increases in obesity due to Western lifestyle and diet has produced a steadily 
increasing prevalence of T2DM the past several decades.  Notably, worldwide prevalence 
of obesity has more than doubled since 1980 [69].  According to 2014 global estimates by 
the World Health Organization, more than 1.9 billion adults (aged 18+) were overweight 
or obese [69].  Overall, approximately 13% of the world’s population were considered 
obese in 2014 [69].  Not only are more adults developing obesity and T2DM, but they are 
developing these complications at an earlier age, like in the Pima population [70].  Early-
onset T2DM has proven especially important for women, because the age at diagnosis 
now coincides more frequently with child-bearing years [71,72].  Although women are 
having children later in their lives than ever before, age during pregnancy can only account 
for a portion of the increased prevalence [73]. 
 
In addition to increasing T2DM diagnoses and maternal ages, the rising rate of obesity 
alone has contributed to increasing pregnancy complications.  Rates of obesity in 
American pregnant women has been reported between 18.5 and 38.5% [71,74].  
Importantly, obesity is a known risk factor for the development of GDM [75,76].  Analyses 
completed by the Centers for Disease Control and Prevention in 2014 suggest that GDM 
currently impacts 9.2% of all pregnancies [77].  Despite shorter disease duration 
compared to T2DM, GDM also has a significant impact on fetal development [78].  
Exposure to GDM in utero leads to both acute and chronic morbidities in children [63,67].  
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Recent studies suggest that intrauterine GDM exposure increases the likelihood for a child 
to develop high blood pressure, cardiovascular disease, T2DM and the metabolic 
syndrome [67].  Presently, no ‘cure’ for GDM exists, but lifestyle guidelines assist with 
disease management to minimize long-term fetal effects.  Current prevention strategies 
include regulating diet and exercise, monitoring blood glucose levels, and, in some cases, 
administering insulin injections [76].  Unfortunately, these strategies rely heavily on patient 
compliance, which is very difficult to control.  Although maternal GDM is often resolved 
following birth, women diagnosed with GDM have increased risk for developing T2DM 
following pregnancy.  Based on the number of individuals affected, the numerous health 
risks associated with the disease, and a lack of successful intervention thus far, it is 
evident that GDM will be a significant health concern for decades to come.  Therefore, 
understanding how the GDM intrauterine environment impacts fetal development will 
contribute to future treatment strategies and preventative therapies.  Specifically, the 
research outlined in this thesis provides novel approaches to identify molecular 
mechanisms altered, following GDM exposure, in a fetal vascular cell population critical 
for vessel formation during development and angiogenesis/vascular repair postnatally.  
Identification of specific mechanisms or gene targets altered in GDM-exposed ECFCs 
through studies such as those presented in this work will guide the development of future 
prevention and treatment strategies. 
 
Maternal T2DM Negatively Alters Endothelial Progenitor Cell Number and Function 
Previously, our lab has demonstrated that exposure to maternal pre-gestational diabetes 
mellitus in utero negatively impacts fetal progenitor cell number and function [79–81].  
These observations are the result of several studies in which primary cell samples were 
either obtained directly from diabetic pregnancies or exposed in vitro to conditions 
intended to recapitulate a component of the diabetic intrauterine environment (i.e. 
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hyperglycemia).  To mimic physiologic hyperglycemia resulting from maternal diabetes, 
umbilical cord blood-derived ECFCs from non-diabetic pregnancies were exposed to high 
concentrations of dextrose (10-30mmol/l) compared to a normoglycemic concentration 
(5mmol/l) for seven days.  Following dextrose treatment, ECFCs incurred dose-dependent 
reductions in colony forming abilities, with a 50% reduction in colony number at the highest 
dextrose concentration tested (30mmol/l) compared to untreated controls [79].  
Additionally, high dextrose treatment (15mmol/l) reduced ECFC vasculogenesis, as 
measured in vitro, by 30% [79].  Thus, exposure to hyperglycemia, at levels comparable 
to those observed in mothers with T2DM, is sufficient to impair ECFC function.  To 
determine if these observations translated in vivo, functional studies were performed using 
ECFC samples derived from T2DM pregnancies.  Similar to the functional deficits 
observed following dextrose treatment, ECFCs exposed to T2DM in utero exhibited 
reduced colony formation, clonogenic capacity and proliferative potential [79].  In addition, 
ECFCs from T2DM pregnancies had altered vasculogenic potential, forming 66% fewer 
networks in vitro compared to samples from uncomplicated pregnancies (Figure 4).  To 
more rigorously assess vessel forming ability, ECFCs from uncomplicated and T2DM 
pregnancies were embedded in gel plugs and transplanted into immunodeficient, NOD-
SCID mice.  Consistent with differences observed in vitro, ECFCs from diabetic 
pregnancies formed 50% fewer perfused vessels compared with ECFCs from 
uncomplicated pregnancies (Figure 5) [79].  Therefore, exposure to a maternal diabetic 
intrauterine environment, and specifically to hyperglycemia, impairs the ability of ECFCs 
to proliferate and undergo vasculogenesis. 
 
To begin to identify the mechanisms underlying the differences in ECFC clonogenic 
capacity and network formation following exposure to hyperglycemia in vitro or intrauterine 
maternal T2DM, senescence and apoptosis were assessed.  Following exposure to in vitro 
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hyperglycemia, a greater percentage of ECFCs underwent cellular senescence compared 
to untreated controls [79].  Similarly, ECFCs isolated from T2DM pregnancies had an 
increased percentage of senescent cells compared to ECFCs from uncomplicated 
pregnancies [79].  No differences were observed in the percentage of ECFCs undergoing 
apoptosis.  Together, these data indicate that senescence is an important mechanism by 
which ECFCs from diabetic pregnancies may incur functional deficits. 
 
Gestational Diabetes Mellitus Alters ECFC Proliferation and Senescence  
In addition to T2DM, GDM, a more common, later-onset form of maternal hyperglycemia, 
also impacts pregnancy outcomes.  Therefore, additional studies were necessary to 
determine if GDM exposure negatively impacts fetal ECFC function to the same extent as 
T2DM.  Similar to ECFCs from T2DM pregnancies, low passage (<5) ECFCs isolated from 
GDM pregnancies exhibited impaired network forming abilities, forming 50% fewer 
networks in Matrigel assays [81].  Interestingly, despite similar defects in network 
formation, low passage ECFCs exposed to GDM do not maintain all phenotypic deficits.  
Specifically, exposure to GDM did not impact ECFC colony formation or senescence at 
low passage, however GDM exposure increased ECFC proliferation compared to ECFCs 
from uncomplicated pregnancies [81]. 
 
Since senescence was identified as an important mechanism impacting ECFC function 
following exposure to maternal T2DM, an in vitro model of ECFC aging was implemented 
to evaluate higher passaged GDM-exposed ECFCs for a predisposition towards a 
senescent phenotype.  To model cell “aging” ECFCs were serially passaged by re-plating.  
Serially passaged GDM-exposed ECFCs were no longer hyper-proliferative, but had an 
increased frequency of senescent cells compared to uncomplicated controls [81]. 
Additionally, in the setting of hyperglycemia (15mmol/l glucose), approximately 10% of 
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ECFCs from non-diabetic pregnancies become senescent while GDM-exposed ECFCs 
were resistant with only 2% of cells staining positive for senescence-associated -
galactosidase [79,81].  Resistance to hyperglycemia-induced senescence is indicative of 
an adaptive response in the ECFCs, enabling them to survive the abnormal intrauterine 
environment.  Thus, the duration and severity of exposure to maternal diabetes, whether 
pre-gestational or gestational, impacts ECFC function differently.  Therefore, it is important 
to identify mechanisms, including differential gene expression and signaling pathway 
activation, that could be underlying these functional differences.  In the work presented in 
this thesis, a combination of quantitative Real-Time Polymerase Chain Reaction (qRT-
PCR), western blotting, and immunofluorescence techniques are used to identify 
differential gene expression and pathway activation in ECFCs from uncomplicated, T2DM, 
and GDM pregnancies. 
 
Maternal Diabetes-induced Alterations in Fetal ECFC Gene Expression and Epigenetic 
Regulation  
Vascular progenitor cell populations, including ECFCs, display significant functional 
impairments as a result of exposure to maternal diabetes in utero [79,80].  However, the 
molecular mechanisms underlying the observed phenotypic differences in number and 
function are unknown.  Therefore, an increasing number of studies have focused on the 
identification and confirmation of differentially expressed genes in vascular progenitor cells 
obtained from diabetic pregnancies [82,83].  Previously, the Haneline laboratory identified 
that ECFCs isolated from GDM pregnancies exhibit alterations in gene expression [83].  
Out of nearly 28,000 genes assessed using microarray analysis, 596 mRNAs were 
significantly altered (p<0.01) in ECFCs from GDM pregnancies compared to 
uncomplicated controls [83].  Of the 596 genes identified, only 38 genes had at least a 
50% increase or decrease in expression.  Interestingly, placenta-specific 8 (PLAC8) was 
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one of the most highly upregulated genes in GDM samples, while ALX homeobox 1 and 
endothelial nitric oxide synthase were significantly down-regulated (described in detail 
below). 
 
Since exposure to intrauterine diabetes produces long-term changes in ECFC gene 
expression, alterations in epigenetic regulation is postulated as the underlying mechanism 
given the stability of these changes over time [84].  Thus, in addition to gene expression, 
the impact of epigenetic regulation on cell fate determination has been increasingly 
studied to understand how suboptimal conditions during development, such as maternal 
diabetes, lead to increased metabolic morbidities later in life [85–88]. Nomura et al. 
identified that global methylation levels in the placenta are lower in women with GDM and 
preeclampsia compared to women without those risk conditions [86].  Similarly, in a study 
by Hajj et al. methylation of genes such as Mesoderm Specific Transcript, and NR3C1 
glucocorticoid receptor were significantly reduced in cord blood and placental tissue from 
GDM patients compared to controls [87].  Finally, in a study by del Rosario et al., pathway 
analysis identified pathways, including the NOTCH signaling pathway, with differentially 
methylated promoters in offspring of diabetic mothers such as Maturity Onset Diabetes of 
the Young (Figure 6) [85].  In combination, these pathway results support the hypothesis 
that altered -cell function could be the mechanism by which offspring of diabetic mothers 
have an increased risk for developing T2DM later in life.  In general, epigenetic and 
pathway analyses provide insight into how offspring with suboptimal development are at 
increased risk for developing future metabolic morbidities. 
 
Epigenetic studies using fetal ECFCs have produced strong evidence that epigenetic 
reprogramming occurs following GDM exposure in humans [83].  Specifically, critical 
regions of the PLAC8 promoter and first intron had reduced CpG methylation in GDM-
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exposed ECFCs compared to uncomplicated controls.  Additionally, DNA methylation 
status of 17 CpG sites in PLAC8 negatively correlated with mRNA expression [83].  Similar 
to PLAC8, correlations between RNA expression and DNA methylation have also been 
identified in the promoter regions of other genes, including Transgelin 1 (r= -0.72, p=0.02, 
FDR =0.28, Emily Blue, unpublished data).  These findings suggest that the alterations in 
gene expression observed in ECFCs from GDM pregnancies could be regulated, in part, 
by epigenetic mechanisms such as DNA methylation. 
 
Implications of Elevated Transgelin 1 in ECFCs from GDM Pregnancies 
Gene expression studies conducted on umbilical cord blood-derived ECFCs identified 
Transgelin 1 (TAGLN) as one of the genes significantly increased in fetal ECFCs exposed 
to GDM.  This is surprising, as TAGLN was initially thought to be smooth muscle-specific 
when discovered in 1987 in chicken [89].  However, TAGLN expression has been 
identified in other cell types, including mesenchymal cells, fibroblasts, and epithelial cells 
[90,91].  Interestingly, this is not the first report of elevated TAGLN in the setting of GDM.  
Increased TAGLN has also been identified in placentas from GDM pregnancies [92].  It is 
speculated that increases in TAGLN, along with other genes associated with chronic 
stress and inflammatory pathways, could link inflammation to GDM-associated insulin 
resistance.  Overall, GDM is a multi-faceted disease with intrauterine exposure likely 
resulting in numerous changes to the developing infant [65,66,93]. 
 
Since the initial discovery, three different Transgelin genes have been identified 
(Transgelin1-3).  TAGLN, also known as SM22α, is an early marker of smooth muscle cell 
differentiation [94].  Transgelin 2 (TAGLN2), otherwise known as SM22β, is a homolog of 
TALGN, but has not been studied to the same extent as TAGLN [95].  The third gene, 
Transgelin 3 (NP25) is primarily expressed in neuronal cells [96].  Abundant literature 
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outlines the function of TAGLN in smooth muscle cells, since expression was thought to 
be specific for that differentiated cell population.  In smooth muscle cells, TAGLN down-
regulation may be an indicator of cellular transformation [91].  Vascular smooth muscle 
cells in a contractile state express high levels of TAGLN and have reduced migration and 
proliferation [97,98].  Upon injury or disease, however, vascular smooth muscle cells can 
switch to a synthetic state, with decreases in TAGLN expression and increases in cell 
migration and proliferation [99–101].  Cellular differentiation studies have not been limited 
to vascular smooth muscle cells.  Recent studies using endothelial stem progenitor cells 
to form vascularized tissue utilized TAGLN as a marker of vascular smooth muscle cell 
differentiation [102,103].  Thus, TAGLN represents an important marker of cellular 
differentiation. 
 
All three Transgelin genes contain the conserved Calponin homology domain and 
Calponin Family Repeat [104].  The Calponin homology domain is an actin-binding domain 
commonly found in cytoskeletal and signal transduction proteins [105].  In this regard, 
TAGLN primarily localizes in the cytoplasm near actin filaments and aids in the formation 
of actin bundles via induction of polymerization of globular actin (G-actin) to filamentous 
actin (F-actin) in addition to promoting F-actin cross-linking [106–109].  Therefore, TAGLN 
is involved in the dynamic process of actin cytoskeletal rearrangement. 
 
The ability of the cells that comprise the vasculature to reorganize their cytoskeleton in 
response to external stimuli is a critical function.  Endothelial cells respond to mechanical 
forces, including fluid shear stress, by modulating intracellular signaling pathways and 
gene expression [110].  Although few studies have assessed the functional role of the 
Transgelin genes in endothelial cells, TAGLN and TAGLN2 have been implicated in 
regulating endothelial cell migration via modulation of matrix metalloproteinase 9 (MMP9) 
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and phosphorylation of myosin light chain, respectively [111,112].  Specifically, TAGLN is 
a regulator of MMP9, such that overexpressing TAGLN in HT1080 (human fibrosarcoma 
line) cells decreased MMP9 expression, and reduced cell invasion in Matrigel trans-well 
assays [112].  Importantly, HT1080 cell migration was rescued by addition of exogenous 
MMP9, suggesting that not only is MMP9 regulated by TAGLN, but, as a Type IV 
collagenase, it is a key component of cell migration [112].  In another study by Xiao et al., 
siRNA-mediated reductions of TAGLN2 were sufficient to increase human umbilical vein 
endothelial cell migration following lovastatin (10M) treatment [111].  Moreover, TAGLN2 
knockdown was associated with increased in myosin light chain phosphorylation, thereby 
implicating myosin light chain activation in TAGLN2-regulated cell migration. 
 
TAGLN is not highly expressed in fetal ECFCs isolated from uncomplicated pregnancies.  
However, exposure to GDM during development increases TAGLN levels in ECFCs.  
Interestingly, elevated TAGLN transcripts were identified in the placenta from GDM 
pregnancies previously [92].  In addition to TAGLN, differentially expressed genes 
associated with chronic stress and inflammatory pathways were also identified.  This is an 
interesting finding, as the authors postulate that it could provide a link between 
inflammation and GDM-associated insulin resistance [92]. 
 
ECFC Functional Assessments Limited by Current Experimental Approaches 
Although several studies have demonstrated that intrauterine exposure to maternal T2DM 
and GDM have long-term effects on child health outcomes, the mechanisms responsible 
are not fully understood.  Improving functional assessment of fetal vascular progenitor 
cells will allow for an understanding of how intrauterine diabetic exposure imparts long-
term vascular complications.  Currently, limited clinical tools are available to assess 
severity of diabetic exposure in children from mothers with T2DM and GDM.  
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Unfortunately, these morbidities often go undiagnosed until children present with disease 
later in life, at which time the opportunity for prevention has ended.  Therefore, in-depth 
analyses of ECFC vasculogenesis are needed to identify how and why functional deficits 
are incurred in utero.  Studies conducted to complete this thesis work address the need 
for in-depth analyses of ECFC vasculogenesis through the development of novel 
microscopic approaches to rigorously assess vessel formation kinetics. 
 
Modeling vasculogenesis enables rapid analysis of cells to perform basic tasks of network 
or vessel formation [113,114].  However, standard methods are limited in scope and fail 
to capture many aspects of this highly dynamic process (Figure 4).  Though attempts have 
been made to apply quantitative analyses, current methods are insufficient for dynamic 
studies [115–117].  Therefore, kinetic assessments are needed to identify mechanisms of 
impaired vasculogenesis.  Specifically, improved assessment of ECFC function following 
intrauterine diabetes exposure, will improve infant risk assessment and inform future 
preventative strategies.  
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Major Aims 
1.     To develop innovative methods to quantitatively assess the kinetics of ECFC 
vasculogenesis in vitro. 
 
2.     To identify novel phenotypic differences in ECFC vasculogenesis following 
exposure to intrauterine diabetes. 
 
3.     To determine if increased Transgelin 1 expression in ECFCs from gestational 
diabetic pregnancies impairs vasculogenesis. 
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Figures (1-6) 
Figure 1. Modes of Vessel Formation 
 
 
 
Vessel formation can occur by angiogenesis where new vessels sprout from pre-existing 
vascular networks.  New vessels can also be formed by vasculogenesis where endothelial 
progenitor cells (EPCs) can differentiated into endothelial cells (ECs) to form new vessels 
in the absence of preexisting vascular structures.  Figure adapted from Carmeliet et al. 
(2011) [2].   
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Figure 2. Notch and VEGF Signaling Regulate Endothelial Tip Cell Formation 
 
 
 
In future tip cells, VEGF-A signaling via VEGFR-2 causes up-regulation of Dll4. Dll4 binds 
Notch molecules on the membranes of adjacent endothelial cells and facilitates receptor 
cleavage by ADAM and γ-secretase/presenilin. Cleavage untethers the Notch intracellular 
domain (NICD) from the membrane, which then translocates to the nucleus and 
complexes with CSL, turning the transcriptional repressor into a transcriptional activator. 
Transcriptional activation has several downstream effects, including the creation of a 
positive feedback loop via increased Notch expression, inhibition of VEGFR-2 expression, 
and up-regulation of VEGFR-1, a receptor with high affinity for VEGF-A but low signaling 
activity. Thus, endothelial cells adjacent to tip cells have greatly reduced sensitivity to 
VEGF-A, and adopt a stalk cell character.  Figure adapted from Tung et al., (2012) [4]. 
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Figure 3. Schematic of the ECFC Single-cell Assay 
 
 
 
HPP-ECFCs are large colonies that form secondary and tertiary colonies on re-plating.  
HPP-ECFCs give rise to all subsequent stages of endothelial progenitors in addition to re-
plating into secondary HPP-ECFCs.  LPP-ECFCs form colonies that contain more than 50 
cells but do not form secondary colonies or LPP-ECFCs on re-plating.  Endothelial cell 
clusters can arise from a single cell but contain fewer than 50 cells that are typically larger 
than the smaller cells found in HPP-ECFC and LPP-ECFC colonies.  Mature, terminally 
differentiated endothelial cells do not divide.  The scale bar represents 100m.  Figure 
adapted from Ingram et al., (2004) [31]. 
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Figure 4. Exposure to Maternal Diabetes Mellitus Reduces Fetal, Cord Blood-derived 
ECFC Network Formation 
 
 
 
Representative photomicrographs of ECFCs derived from uncomplicated (C) and pre-
gestational diabetic pregnancies (IDM) 24 hours after plating on Matrigel.  Results are 
representative of three independent experiments.  The scale bar represents 30m.  
Quantitation of capillary vessel density 24 hours after plating on Matrigel.  Data represent 
mean +/- SEM, n=4, *P<0.002 by Student‘s t test.  Figure adapted from Ingram et al., 
(2008) [79].  
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Figure 5. Maternal Diabetes Mellitus Exposure Reduces Fetal, Cord Blood-derived ECFC 
Vessel Formation 
 
 
Representative photomicrographs (100x magnification) of cellularized grafts and 
surrounding murine tissue14 days after implantation into NOD/SCID mice stained with 
anti-human CD31 (brown) to identify human blood vessels.  Grafts contained ECFCs from 
either uncomplicated (C) or pre-gestational diabetic pregnancies (IDM).  Arrows indicate 
anti-human CD31+ vessels and capillaries in the ECFC grafts, which were perfused with 
murine erythrocytes.  Results shown are representative of three independent experiments 
using cells from different donors.  Quantitation of capillary density within cellularized grafts 
containing ECFCs from uncomplicated or diabetic pregnancies 14 days after implantation.  
Results represent the average number of capillaries containing murine erythrocytes/mm^2 
of graft tissue +/- SE, n=3, *P<0.001 by Student‘s t test.  Figure adapted from Ingram et 
al., (2008) [79]. 
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Figure 6. Pathways for Maturity Onset Diabetes of the Young (MODY) and Notch Signaling 
 
 
 
Maturity Onset Diabetes of the Young (hsa04950) and Notch signaling pathways 
(hsa04330); adapted from Kanehisa et al. [118]. Genes in the pathways which are hyper-
methylated in ODM compared with ONDM are shown in red boxes, while hypo-methylated 
genes are shown in blue boxes. Genes that did not show differential methylation are in 
gray boxes. Boxes for INS and CTBP2 are marked with both red and blue indicating that 
two separate regions with different methylation status overlapped with the promoter of 
these two genes.  Figure adapted from del Rosario et al., (2014) [85]. 
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Umbilical Cord Blood Sample Acquisition 
Umbilical cord blood samples were collected at the time of birth following written informed 
consent from the mothers.  Samples were obtained from women with uncomplicated (UC) 
pregnancies and from women diagnosed with type 2 diabetes mellitus (T2DM) prior to 
pregnancy.  All pregnancies were single gestation.  Infants with known chromosomal 
abnormalities were excluded. Women with preeclampsia or hypertension, women with 
other illnesses known to affect glucose metabolism, and women taking medications known 
to affect glucose metabolism were excluded.  Clinical data from women and infants are 
summarized in Tables 1 and 2, respectively.  No significant differences were identified 
between the UC and T2DM groups for the following clinical values: maternal age, pre-
pregnancy BMI, gestational age, infant weight, infant weight percentile, infant 
weight/length percentile, and ponderal index (all p-values >0.05). 
 
ECFC Cell Culture 
ECFCs were isolated from umbilical cord blood samples as previously described (Figure 
7) [79,81].  Umbilical cord blood was diluted 1:1 with PBS and underlaid with Ficoll-Paque 
PLUS (GE Healthcare, Piscataway, NJ).  The blood was centrifuged for 30 minutes at 
740g.  Mononuclear cells were isolated from the buffy coat and washed with Endothelial 
Growth Medium 2 (Lonza, Walkersville, MD) containing 10% Hyclone defined fetal bovine 
serum (FBS, ThermoFisher Waltham, MA), antibiotic-antimycotic solution (Corning, 
Manassas, VA), and MycoZap PR antibiotic (Lonza) (EGM2+10%FBS).  Mononuclear 
cells were resuspended in EGM2+10%FBS and plated in six-well tissue culture plates pre-
coated with type 1 collagen (Corning).  Following 24 hours in culture, all wells were washed 
with EGM2+10%FBS to remove non-adherent cells, and medium was changed daily for 7 
days and then on alternate days until first passage.  ECFC colonies appeared between 5-
8 days of culture.  After reaching confluence, cells were detached with 0.25% trypsin-
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EDTA (Invitrogen, Grand Island, NY) and frozen in 5% dimethyl sulfoxide (ThermoFisher) 
in FBS (Atlanta Biologicals, Flowery Branch, GA).  ECFC aliquots were thawed, 
resuspended in EGM2+10%FBS, and plated on type 1 collagen coated flasks for culture.  
ECFCs used in these studies were passaged 2-5 times. 
 
Workflow forAcquiring and Assaying Cord Blood-derived ECFCs 
The overall approach in conducting these assays involved three stages (1-3) (Figure 7).  
First (1), in the Cell Sample Preparation stage, umbilical cord blood samples were 
collected at the time of birth and processed for derivation of ECFC colonies.  This stage 
is described in detail in the Umbilical Cord Blood Acquisition and ECFC cell culture Method 
sections.  The second stage (2) of the process primarily involved image acquisition.  
Several different imaging modalities were utilized to obtain photomicrographs for the newly 
developed assays including phase contrast microscopy, confocal microscopy, and 
conventional fluorescence microscopy.  In the Kinetic Network Formation and Motility 
assays, phase contrast or fluorescence images were acquired every 10-15 minutes over 
the course of several hours, allowing for an in-depth assessment at network formation 
kinetics.  Importantly, acquiring large numbers of images in stage 2 necessitated the third 
stage (3) of assay development, which was data analyses.  In this stage, images were 
processed, and new software was developed to measure new phenotypes with the goal 
of identifying novel biologic phenomena. 
 
Matrigel Assay Setup for KAV Experiments 
ECFCs (passage 3-4) were plated at 400,000 cells per 100mm dish and incubated 
overnight.  The following day, ECFCs were trypsinized (ThermoFisher), counted on a 
hemocytometer, and plated at equal densities in EGM2 supplemented with 10% FBS.  
ECFCs were plated on 10ul of Matrigel lot #4209014 (Corning) in 15 well μ-slides (Ibidi 
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USA, Inc.).  The slide containing Matrigel was placed in the microscope stage-top 
incubator to maintain temperature, CO2, and humidity, for overnight live cell imaging.  
Images of entire wells were collected using a cooled charge-coupled device (CCD) 
camera (Hamamatsu ORCA-ER) every 15 minutes for 15 hours for a total of 60 data points 
per ECFC sample in each experiment. 
 
Microscopy Settings and Equipment for KAV Experiments 
All imaging for KAV experimentation was performed on a fully automated Nikon TiE 
microscope equipped with a ProScan II motorized stage (Prior Scientific, Rockland, MA), 
xenon lamp source, Lambda LS, and Lambda 10-3 filter wheel controller (Sutter 
Instrument Company, Novato, CA), fitted with an ORCA-ER or ORCA-Flash 4.0 
(Hamamatsu, Japan) controlled by Elements 4.20 (Nikon Instruments Inc., Melville, NY).  
Fluorescent filters were the Quad Sedat v89000 set (Chroma Technologies, Bellows Falls, 
VT).  Experiments with phase contrast imaging used a CFI PlanFluor DLL 10X objective 
and those with fluorescence imaging for contrast used a CFI S Plan Fluor ELWD ADM 
20x objective (Nikon Instruments Inc.).   Multiple images and Z-positions were collected 
to cover the sample wells and stitched together with Elements as required.  For live 
imaging the microscope was fitted with a stage top incubator with humidity (75-85%), 
temperature (37ºC) and CO2 regulation (5%; OkoLab, Burlingame, CA). 
 
Kinetic Analysis of Vasculogenesis (KAV) 
Phase contrast images were compiled, processed, and analyzed using a custom FIJI 
plugin called Kinetic Analysis of Vasculogenesis (KAV) created by Seth Winfree in the 
Indiana Center for Biological Microscopy specifically for completion of this project.  For 
image processing and analysis details see Appendices E and F on Protocols for 
Automated Network Analysis in FIJI (Image J).  KAV utilizes the Skeletonize 2D/3D and 
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Analyze Skeleton plugins in FIJI [119].  The software allowed for quantification of 8 distinct 
parameters of vasculogenesis over time including closed networks, network area, nodes, 
branches, the ratio of branches to nodes, branch length, nodes with 3 branch extensions, 
and nodes with 4 branch extensions.  A closed network was defined in KAV as an enclosed 
area surrounded by cells.  Network area is the size of the closed network openings.  
Definitions for nodes and branches were created to differentiate the structures in KAV.  
Nodes were defined as points within the network that have 3-4 branch extensions.  Nodes 
with more than 4 branch extensions were not observed.  A structure connected on at least 
one end by a node was defined as a branch.  However, branches could be connected on 
both ends as indicated by the branches in Figure 9.  KAV calculated the ratio of branches 
to nodes by dividing the total number of branches by the total number of nodes detected 
in a well.  The values generated from the software analysis were graphed in Prism 
(Graphpad, San Diego, CA) and R (version 3.1.1) [120]. 
 
Matrigel Immunofluorescence Technique 
Matrigel assays were conducted and analyzed at time points indicated using 
immunofluorescence staining [121].  Briefly, the samples were fixed with 4% 
paraformaldehyde five hours post-plating, permeabilized with 0.5% Triton X-100 in 
phosphate buffered saline (PBS), quenched with 100mM glycine, and blocked with 0.1% 
bovine serum albumin, 0.2% Triton X-100, 0.05% Tween-20, and 10% goat serum 
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) in PBS.  Samples were 
incubated with alpha-tubulin primary antibody at a 1:1000 dilution (#T6199, clone DM1A, 
Sigma-Aldrich, St. Louis, MO) overnight at room temperature.  The following day, 
Alexa568-conjugated goat anti-mouse secondary antibody (#A11031, ThermoFisher 
Scientific) was added at 1:400 for 40 minutes at room temperature.  Samples were imaged 
in PBS containing NucBlue Fixed Cell Stain Ready Probes reagent as recommended by 
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the manufacturer (#R37605, ThermoFisher Scientific) on the Nikon TiE inverted 
microscope with a xenon lamp source and fluorescent filters (Chroma Inc., Bellows Falls, 
VT).  Negative controls lacking primary antibody did not show nonspecific secondary 
antibody staining.  The alpha-tubulin antibody clone DM1A was selected because of its 
specificity as determined by Western blotting, which produces a single band at 50kDa in 
ECFCs (data not shown).  Also, immunofluorescence staining for alpha-tubulin by DM1A 
yields identical staining to a separate clone that binds a different epitope on alpha-tubulin 
[122].  To ensure full coverage of the samples 6 z-planes were collected at 15 m steps.  
The cells were imaged using a 20x objective on a Leica SP8 MP microscope. 
 
Tissue Cytometry (TC) to Identify Mitotic Cells 
Immunofluorescence images were processed and analyzed using the tissue cytometry 
(TC) software, Volumetric Tissue Exploration and Analysis (VTEA) [123].  For a detailed 
protocol see Appendix A: Protocol for Analyzing Immunofluorescence Mitotic Index 
Images.  The software allows for single-cell quantification of both nuclear and cytoplasmic 
fluorescence intensities in three dimensions. A spatial measurement to assess the 
localization of cells within the network structures (i.e. branches and nodes) is 
accomplished using a combination of the original image volume and a scatter plot of cell 
associated signals.  Populations of cells on the scatterplot were interrogated with a 
“gating” tool similar to flow cytometry, enabling quantitative analysis.  Cells were identified 
by their nuclei following nuclear staining with NucBlue Fixed Cell Stain Ready Probes 
reagent (#R37605, ThermoFisher Scientific).  The intensity of NucBlue staining was used 
to assess for mitotic cells.  In some cases, a well-characterized antibody against phospho-
Histone H3 was used to confirm accuracy of this approach [phospho-histone H3 staining 
(Ser10) conjugated to Alexa488 at a 1:50 dilution (#9708, Cell Signaling Technology) 
[124].  The accuracy of NucBlue intensity as an indicator of mitotic vs. non-mitotic cells, 
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and intensity thresholds for each experiment were assessed manually on a sub-region of 
one volume from each dataset.  Between all experiments the specificity, precision, and 
accuracy were 96.8 ± 1.3%, 56 ± 5.2%, and 96.5 ± 1.2% respectively (mean ± SD).  Branch 
and node thickness were determined with the Local Thickness tool in FIJI, which 
generated a distance map and hence thickness of a mask derived from microtubule 
staining of the network.  This distance map was added as a channel to facilitate image 
analysis with VTEA. 
 
Flow Cytometric Proliferation Analysis 
Baseline ECFC proliferation was evaluated by flow cytometry on cells in standard culture 
conditions. Cells were washed with 2% FBS in PBS, re-suspended in cytofix/cytoperm 
buffer (BD Biosciences, San Jose, CA), and incubated for 20 minutes on ice.  Cell 
suspensions were washed twice with perm/wash buffer (BD Biosciences), followed by 
incubation with phospho-histone H3 (Ser10) conjugated to Alexa488 (#9708, Cell 
Signaling Technology) for 45 minutes in the dark at 37ᵒC.  The suspensions were washed 
again with perm/wash buffer and re-suspended in 2%FBS in PBS for flow cytometric 
analysis.  Samples were analyzed using an LSRII flow cytometer (Becton Dickinson, San 
Jose, CA) with at least 10,000 events collected per sample.  FlowJo software (TreeStar, 
Inc., Ashland, OR) was used in analysis. 
 
Stable Expression of GFP using Lentivirus for Single Cell Assay 
The lentiviral vector plasmid (pUC2CL6IPwo), packaging accessory plasmid (pCD/NL2), 
and envelope plasmid (pVSVG) were generous gifts from Helmut Hanenberg (Heinrich 
Heine University School of Medicine, Düsseldorf, Germany) [125].  Lentiviral particles 
were produced by transfection of HEK293 cells with the pUC2CL6IPwo vector plasmid 
containing GFP (1.67 g/ml), the pCD/NL2 packaging accessory plasmid (1.16 g/ml) and 
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the VSVG envelope plasmid (1.16 g/ml) using Fugene 6 (Roche Applied Science, 
Indianapolis, IN).  Lentiviral supernatants were collected and filtered through a 0.45-m 
asymmetric polyethersulfone filter unit (ThermoFisher).  Supernatants were used 
immediately or stored at -80C for future use. 
 
Single Cell Assay 
ECFCs were plated at 250,000 cells per dish in 100mm type 1 collagen-coated tissue 
culture dishes.  The following day, lentiviral supernatant (GFP: described above) was 
added to each dish at dilutions of 1:2-1:10 and the cells were incubated overnight at 37°C.  
The media (EGM2+10%FBS) was changed 24h after transduction, and cells were 
incubated for a second overnight at 37°C.  The second day after transduction, the ECFCs 
were removed from the dishes using Trypsin (ThermoFisher), washed, and resuspended 
in 2%FBS in PBS.  GFP was used to select the brightest 15% of all transduced ECFCs, 
which were then sorted by FACS.  One cell was sorted into each well of 96 well collagen-
coated dishes containing 100µl of EGM2+10%FBS media, using a BD SORP Aria at the 
Flow Cytometry Research Facility in the IU Simon Cancer Center (Indianapolis, IN).  
Culture media was changed on day 7.  On day 14 of culture wells were examined to 
quantitate the number of cells using a fluorescent microscope.  Wells with endothelial cell 
counts of 2-50, 51-500, 501-2,000, and ≥ 2,001 were labeled as endothelial cell clusters 
(ECCs), low proliferative potential ECFCs (LPP), and high proliferative potential ECFCs 
(HPP) respectively and as previously described [17,32] (Figure 3).  Results were graphed 
and statistical analysis was completed in Prism (GraphPad Software). 
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Baculoviral System for Nuclear GFP Expression  
ECFCs (passage 3-4) were split and incubated using standard culture conditions 
overnight.  The following day, Cell Light Nuclear-GFP BacMam2.0 (ThermoFisher 
Scientific) was added at a multiplicity of infection (MOI) of 30.  The cells were incubated 
overnight, and then processed for Matrigel assays as described in the method for Matrigel 
Assay Setup for KAV Experiments. 
 
TrackMate Motility Analysis 
Images were processed in Elements (Nikon Instruments Inc.) and FIJI [126]. For a detailed 
description of image processing see Appendix B: Protocol for Processing Fluorescence 
Images in FIJI (ImageJ) for Trackmate.  FIJI TrackMate was used to analyze cell motility 
parameters including displacement and speed.  In TrackMate, the difference of Gaussian 
(DoG) detector was used with an estimated spot diameter of 25.0 pixels and a threshold 
of 2.0 for individual cell nuclei detection.  The Simple LAP tracker with a linking max 
distance of 50 microns, a gap-closing max distance of 90 microns, and a 4 frame max 
gap-closing was used for tracking the cells through the time course images.  Data from 
the TrackMate analysis were then analyzed using R, a programming language and 
software environment for statistical computing [120]. 
 
Quantitative Real-Time PCR 
ECFCs were plated on collagen-coated cell culture dishes and lysed in Qiazol (Qiagen, 
Valencia, CA).  RNA was obtained using the manufacturer’s instructions and reverse 
transcribed using the Transcriptor Universal cDNA Master Kit (Roche Diagnostics, Risch-
Rotkreuz Switzerland).  Quantitative PCR was performed using Lightcycler 480 (Roche).  
Transgelin levels were normalized to hypoxanthine phosphoribosyltransferase (HPRT) 
using the 2-ΔΔCt method.  Detection of Transgelin 1 and hypoxanthine 
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phosphoribosyltransferase was performed on samples in duplicate using Lightcycler 480 
SYBR Green I Master Mix (Roche) and the following primers: Transgelin 1 5’–
GGCAGCAGTGCAGAGGAC-3’; 5’–TTATGCTCCTGCGCTTTCTT-3’, MMP9 5’–
GAACCAATCTCACCGACAGG-3’; 5’–GCCACCCGAGTGTAACCATA-3’, and HPRT 5’-
CCTTGGTCAGGCAGTATAATCCA-3’; 5’–GGTCCTTTTCACCAGCAAGCT-3’. 
 
RNA Isolation on Matrigel 
ECFCs (passage 3-4) were suspended in EGM2 (Lonza) and 34,000 cells were plated in 
a 24-well tissue culture plate (Corning) pre-coated with 160l of Matrigel per well (lot 
#4209014, Corning).  ECFCs were incubated at 37°C prior to RNA isolation using Qiazol 
(Qiagen).  A Direct-zol RNA MicroPrep kit (R2060, Zymo Research, Irvine, CA) was used 
for RNA purification.  RNA was reverse transcribed using the Transcriptor Universal cDNA 
Master Kit (Roche) and quantitative PCR was performed using Lightcycler 480 (Roche). 
 
Western Blotting 
Whole-cell ECFC lysates were collected using radio-immunoprecipitation assay (RIPA) 
buffer containing Complete Protease Inhibitor Cocktail (Roche Diagnostics).  Equal 
amounts of protein were separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis in 4-12% Bis-tris precast gels (Life Technologies, Grand Island, NY) run 
at 125 volts for 95 minutes.  Protein was transferred onto nitrocellulose membrane at 24V 
for 16 hours at 4ºC.  Immunoblotting was performed with antibodies to Transgelin 1 
(ab14106, Abcam, Cambridge, MA), Vinculin (VIN-11-5, Sigma-Aldrich, St. Louis, MO), 
MYC-Tag 9B11 (#2276, BCell Signaling Technology, Danvers, MA), Phospho-Myosin 
Light Chain 2 (#3674 THr18/Ser19) (Cell Signaling Technology), and Anti-MYL12B 
(ab137063, Abcam).  Secondary antibodies conjugated to horseradish peroxidase were 
obtained from BioRad (Hercules, CA), and blots were developed using Clarity Western 
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ECL Substrate (BioRad).  Band intensity was quantified using Image J (NIH, Bethesda, 
MD). 
 
siRNA Transfections of ECFCs 
ECFCs were plated at 300,000 cells per 100mm tissue culture dish in EGM2 + 10% FBS 
the day of transfection.  Lipofectamine (ThermoFisher Scientific, Waltham, MA) and short 
interfering RNA (siRNA) mixes were prepared in EBM2 (Lonza America, Inc., Allendale, 
NJ), and ECFCs were transfected with either TAGLN-specific (J-003714-08-0002, GE 
Dharmacon, Lafayette, CO) or a non-targeting control siRNA (D-001210-05-05, GE 
Dharmacon, Inc.).  RNA samples and protein lysates were collected and analyzed, as 
described in the Quantitative Real-Time PCR and Western Blotting method sections 
respectively, to confirm knockdown for each transfection. 
 
Generation of Lentivirus Encoding Transgelin cDNA Construct 
The lentiviral vector plasmid (pUC2CL6IPwo), packaging accessory plasmid (pCD/NL2), 
and envelope plasmid (pVSVG) were generous gifts from Helmut Hanenberg (Heinrich 
Heine University School of Medicine, Düsseldorf, Germany) [125].  The TAGLN cDNA 
insert was amplified from ECFC-derived cDNA using the following primers: 5’–
ATGGCCAACAAGGGTCCTTCC—3’; 3’—ACTGATGATCTGCCGAGGTCG—5’.  The 
TAGLN insert was then cloned into the pUC2CL6IPwo vector plasmid using infusion 
cloning with the In-Fusion HD Cloning Kit (Takara Bio USA, Inc., Mountain View, CA) and 
the following primers: 5’—GCGGCCGCAACTCGAGATGGCCAACAAGGTCCT—3’; 3’—
GCTGGAGCCGTCTAGTAGTCAATCCGATCGTAGCTTAAGA—5’.  Lentiviral particles 
were produced by transfection of Lenti-X 293T cells with either the pUC2CL6IPwo 
lentiviral vector (empty vector control) (1.67 g/ml), or the pUC2CL6IPwo lentiviral vector 
containing the TAGLN insert (1.67 g/ml), in addition to the pCD/NL2 packaging accessory 
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plasmid (1.16 g/ml) and the VSVG envelope plasmid (1.16 g/ml) using Fugene 6 (Roche 
Applied Science, Indianapolis, IN).  All lentiviral vectors contain a puromycin resistance 
cassette, which enabled a two-day selection of virally transduced ECFCs (described 
below).  Lentiviral supernatants were collected and filtered through a 0.45-m asymmetric 
polyethersulfone filter unit (ThermoFisher).  Supernatants were used immediately, or 
stored at -80C for future use. 
 
Lentiviral Transduction of ECFCs for Expression of TAGLN 
ECFCs were plated at 250,000 cells per 100mm tissue culture dish the day before 
transduction.  Lentiviral vector supernatant was added to each plate in a 1:10 dilution for 
a final volume of 6 ml of EGM2 + 10% FBS and incubated overnight.  The medium was 
changed and the cells were incubated for 48 hours.  Transduced cells were selected in 
media containing 1 g/ml puromycin (Life Technologies) for two days.  Protein lysates 
were obtained as described, and Transgelin and MYC-tag expression levels were 
confirmed for each transduction by western blotting. 
 
Matrigel Assay (General) 
ECFCs (passage 3-4) were plated at 400,000 cells per 100mm dish in EGM2+10%FBS 
and incubated overnight at 37°C.  The following day, ECFCs were removed from the 
dishes using Trypsin (ThermoFisher), counted on a hemocytometer, and plated at equal 
densities in EGM2.  ECFCs were plated on 10ul of Matrigel lot #4209014 (Corning) in 15 
well μ-slides (Ibidi USA, Inc.) and incubated at 37°C.  Images of entire wells were then 
acquired using a Spot camera (Spot Imaging, Sterline Heights, MI) on an Axiovert 35 
microscope (Zeiss, Thornwood, NY) at times indiciated in the figure legends.  The number 
of closed networks per well was scored and averaged for each condition.  A protocol for 
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Matrigel Assay image processing can be found in Appendix D: Protocol for Merging 
Images in Photoshop. 
 
Trans-well Migration Assay 
ECFCs were plated on collagen-coated transparent PET membranes (24 well, 8.0µm pore 
size) (Corning, Inc.) in EBM2 and incubated at 37ºC for 1-4 hours.  The pro-migratory 
stimulus used was EGM2 + 10% FBS.  Non-migratory cells were removed with cotton 
swabs, and cells were fixed with ice-cold methanol prior to staining with crystal violet.  
Eight different field images were obtained at 20X magnification for each sample and 
quantified.  Images were obtained using a Spot camera (Spot Imaging Solutions) on an 
Axiovert 35 microscope (Zeiss).  Refer to Appendix C: Protocol for Overlapping Separate 
Images in Photoshop for detailed protocol overviews. 
 
Rho Kinase Inhibitor Assay 
In trans-well assay set-up, cells were treated with 0.1M rho kinase inhibitor Y27632 prior 
to plating in the assay. These cells were in rho kinase inhibitor for 4 hours during migration 
assay. For protein collection, cells in 6-well dishes plated the day before we treated with 
0.1M rho kinase inhibitor for 4 hours before being collected with RIPA. 
 
Shear Stress Assay 
ECFCs were plated in confluence on collagen-coated glass slides in EGM2+10%FBS.  
Cells were subjected to laminar flow for 7 hours as previously described [127,128].  
Following exposure to flow, slides were fixed with 4% paraformaldehyde, quenched with 
100mM glycine, blocked with 3% bovine serum albumin, and permeabilized with 0.5% 
Triton X-100 in 3% bovine serum albumin.  Portions of the slide were incubated with 
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Transgelin 1 primary antibody at a 1:400 dilution (ab14106, Abcam, Cambridge, MA) for 
1 hour at room temperature.  AlexaFluor 568-conjugated goat anti-rabbit secondary 
antibody (1:400) (#A11011, Life Technologies) NucBlue Fixed Cell Stain Ready Probes 
reagent (#R37605, ThermoFisher Scientific), and ActinGreen 488 Ready Probes reagent 
(#R37110, ThermoFisher Scientific) were added for 30 minutes at room temperature.  
Slides were rinsed with phosphate buffered saline and mounted with Prolong Diamond 
Antifade mountant (P36970, ThermoFisher Scientific).  Images were acquired using a 
Spot RT XE camera (Spot Imaging, Sterline Heights, MI) with a 40X objective on a Leica 
DM 4000B microscope (Leica Microsystems, Buffalo Grove, IL).  Fluorescence images of 
F-actin were analyzed using the FIJI Directionality Plug-in [129,130].  All mean angle 
values produced by the Directionality Plug-in were used to generate the histograms and 
statistical analysis of angle means and variance. 
 
Actin Centrifugation Assay 
This protocol was adapted from the Gunst laboratory [131].  Briefly, ECFCs were 
homogenized in 200 μl of F-actin stabilization buffer (50 mm PIPES, pH 6.9, 50 mm NaCl, 
5 mm MgCl2, 5 mm EGTA, 5% glycerol, 0.1% Triton X-100, 0.1% Nonidet P-40, 0.1% 
Tween-20, 0.1% β-mercaptoethanol, 0.001% antifoam, 1 mm ATP, 1 μg ml−1 pepstatin, 
1 μg ml−1 leupeptin, 10 μg ml−1 benzamidine and 500 μg ml−1 tosyl arginine methyl 
ester).  Supernatants of the protein extracts were collected after centrifugation (Beckman 
Coulter Optima MAX Ultracentrifuge, Danvers, MA, USA) at 150,000 g for 60 min at 37°C.  
The pellets were resuspended in 200 μl of ice-cold water containing 10 μm cytochalasin 
D and then incubated on ice for 1 h to depolymerize F-actin.  The resuspended pellets 
were gently mixed every 15 min.  Four microlitres of supernatant (G-actin) and pellet (F-
actin) fractions were subjected to immunoblot analysis using anti-actin antibody (clone 
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AC-40; Sigma, St Louis, MO, USA).  The ratios of F-actin to G-actin were determined 
using densitometry. 
 
F-actin Assessment by Flow Cytometry 
ECFCs were plated at 400,000 cells per 100mm dish in EGM2+10%FBS and incubated 
overnight at 37°C.  The following day, the ECFCs were removed from the dishes using 
Trypsin (ThermoFisher) and cell counts were obtained manually using a hemocytometer.  
Cells (150,000) were aliquoted into to 5mL flow cytometry tubes (1 unstained control and 
1 stained tube for each sample) and washed with 1 milliliter of PBS (ThermoFisher).  The 
cell suspension was pelleted by centrifugation for 5 minutes at 1500rpm and the 
supernatant was aspirated.  The cells were resuspended in 500μl of Cytofix/Cytoperm 
buffer (BD Biosciences) and incubated on ice for 20 minutes. Five milliliters of 1X 
Perm/Wash Buffer (BD Biosciences) was added to the cell suspension and mixed gently.  
The cell suspension was pelleted by centrifugation for 5 minutes at 1500rpm, and the 
wash was repeated a second time with an additional 5 milliliters of 1X Perm/Wash Buffer.  
The ActinGreen 488 Ready Probes reagent (#R37110, ThermoFisher Scientific) was 
diluted in Perm/Wash Buffer (BD Biosciences) by adding 2 drops of the probe per milliliter 
of buffer.  500µl of the diluted Ready Probes mix was added to gently resuspend the cell 
pellet, and the suspension was incubated in the dark for 20 minutes at room temperature.  
Cell suspensions were washed with 2 milliteres of 1X Perm/Wash Buffer and pelleted by 
centrifugation for 5 minutes at 1500rpm.  The supernatant was aspirated and the pellets 
were resuspended in 300μl of 2%FBS in PBS.  Samples were then analyzed by flow 
cytometry immediately on an LSR II. 
 
   42 
Statistical Analysis 
The kinetic network formation graphs for KAV data were created in Prism 6.  The graphs 
represent the mean values ± SEM at each time point for the sample sizes indicated in the 
figure legends.  To statistically analyze the differences between the entire kinetic curves, 
individual time point data were integrated to produce estimated mean difference curves 
and the corresponding 95% confidence intervals.  These curves were generated using the 
spline smoothing technique, and the analysis was performed using the MGCV package in 
R, a programming language and software environment for statistical computing [120,132].  
For histogram generation to analyze ECFC motility, the frequency of phenotype 
distribution was plotted such that x and y-axis ranges were kept constant for each variable 
between Phases 1 and 2.  Data were binned based on fixed values described below, with 
bin sizes remaining consistent across phases.  The bin sizes were as follows: 
Displacement 15, Mean Speed 0.005, and Max Speed 0.0015.  Correlations of 
Displacement, Mean Speed and Max Speed were calculated using Phase 1 and Phase 2 
motility data from both UC and T2DM samples.  The Pearson product-moment correlation 
coefficient and the 95% confidence interval were computed in R.  For models of kinetic 
and motility data correction, a multi-level model was built to test linear relationships 
between KAV and motility variables. The models incorporated Phase 1 motility data from 
all 20 ECFC samples (10 UC and 10 T2DM).  Log transformations were applied to all three 
motility variables to normalize the distributions.  Due to the sample size, simple linear 
regression models were utilized for analysis of kinetic data associations.  P-values less 
than 0.05 were considered significant.  One-way ANOVAs were performed on 
comparisons of more than two groups, as indicated in the figure legends.  Paired t-tests 
were conducted when only two groups were compared in knockdown and over-expression 
studies and data were normally distributed.  All basic graphing and statistics were carried 
out in Prism (GraphPad Software, La Jolla, CA) unless otherwise noted. 
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Code Availability 
Codes for KAV and image processing can be found online at: https://github.com/icbm-
iupui/kinetic-analysis-vasculogenesis [133].  
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Figure 7 and Tables (1-2) 
 
Table 1. Clinical Data for Maternal Subjects 
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Table 2. Clinical Data for Infant Subjects 
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Figure 7. Workflow for Acquiring and Assaying Cord Blood-derived ECFCs 
 
 
 
The first stage (1) of the workflow was cell sample preparation from human blood samples.  
Blood was isolated from the umbilical cord immediately following birth and processed for 
the derivation of mononuclear cells which were plated, as previously described, to isolate 
ECFCs [31].  ECFCs were cultured and passaged in tissue culture dishes containing 
EGM2+10% FBS.  Prior to image acquisition, ECFCs were plated in μ-slide wells 
containing Matrigel, where they formed network structures.  In the second stage (2), 
images of the entire μ-slide wells were acquired.  Time-lapse phase contrast images were 
captured and used in kinetic analysis of network formation.  Static fluorescent images were 
acquired for assessment of proliferation on Matrigel.  Additionally, fluorescent time-lapse 
images of ECFCs expressing nuclear GFP were captured to quantitate cellular motility.  
Once the images were acquired, the third stage (3) in the workflow involved the 
implementation of novel data analyses developed to assess ECFC function in vitro.  
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CHAPTER 3: RESULTS 
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Aim 1:  To develop innovative methods to quantitatively assess the kinetics of 
ECFC vasculogenesis in vitro. 
 
Dynamic Assessment of Neonatal ECFC Vasculogenesis 
Current quantification methods of network formation are largely static, providing limited 
insight into potential mechanisms that contribute to functional deficits.  To obtain a realistic 
depiction of the dynamic process of vasculogenesis, new assays were developed to 
measure the kinetics of umbilical cord-blood-derived ECFC network formation in real-time.  
ECFC samples derived from uncomplicated pregnancies were used to establish the new 
assays and perfect the analysis.  In the Kinetic Network Formation assay, longitudinal data 
were analyzed from phase contrast images over 15 hours.  To derive quantitative data, an 
analysis plug-in was created by myself and Seth Winfree for the FIJI image-processing 
package [126], which will be referred to as Kinetic Analysis of Vasculogenesis (KAV).  KAV 
uses image segmentation followed by skeletonization to analyze network components 
from phase contrast images (Figure 8).  The segmentation and skeletonization processes 
produce skeleton and mask renditions of the network structure, which are used to derive 
eight parameters (7 measured, 1 calculated) of network formation quantitated by KAV 
(Figures 8 and 9).  Videos showing representative phase contrast, skeleton, and mask 
renditions from all time points analyzed are available online [133]. 
 
The seven parameters measured by KAV include: closed networks, network areas, nodes, 
branches, branch length, triple-branched nodes, and quad-branched nodes (Figure 9).  
These parameters were chosen to evaluate network structure and connectivity because 
of use in previous studies or their descriptive nature [115].  Using time-lapsed imaging of 
ECFC vasculogenesis coupled with KAV, several interesting observations were made.  
Closed networks increased for the first 4-5 hours and decreased thereafter (Figure 9), 
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suggesting that network formation occurs in two distinct phases.  Concurrently, average 
network area initially decreased followed by increased network area (Figure 9).  Total 
nodes and branches in the overall network structure steadily decreased in the first 10 
hours and then stabilized. Quantitated KAV parameters provided a detailed summary of 
network components, however these measurements do not assess node connectivity.  
Given the observation of unstable or “broken” branch connections in some ECFC samples, 
KAV software was programmed to calculate a branch-to-node ratio, as an assessment of 
network connectivity.  KAV identified that the branch-to-node ratio decreased in the first 5 
hours as connectivity of the network increased, and then remained unchanged from 5-10 
hours as the network structure became stable (Figure 9).  After 10 hours, the ratio of 
branches to nodes increased slightly, indicative of node condensation and branch de-
stabilization.  In total, 5 hours post-plating was identified as a critical time point in network 
formation and represented the time of maximal network connectivity.  By 5 hours, the 
essential components of the network were established with subsequent changes in 
structure being indicative of structure stability and/or remodeling.  Identification of this 
critical time point guided later studies, such that the first 5 hours is referred to as Phase 1 
and 5-10 hours is referred to as Phase 2. 
 
Reproducibility of the Kinetic Network Formation assay was validated by evaluating a 
single ECFC sample on multiple days (Figure 10A-B).  The mean ± standard deviation for 
sample values across three different days show assay variability (Figure 10A).  The 
calculated coefficient of variation, or the ratio of the standard deviation to the mean, is 
another measure of data variability often used to analyze data sets with varying mean 
values.  The coefficient of variation for the number of closed networks measured by KAV 
over three experimental days was between 8-15% across 15 hours of network formation, 
with the lowest values occurring near 5 hours post-plating (Figure 10B).  To validate the 
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accuracy, a comparison was made between the traditional method of manual scoring and 
KAV (Figure 10C-E).  Total networks and nodes identified by KAV were comparable to 
manual counts (Figure 10C-D). KAV detected slightly more branches than identified 
manually (Figure 10E).  Given the difficulty in scoring >200 branches per well, this 
observation suggests that KAV may be more sensitive.  Therefore, this novel, validated 
analytic method provides a longitudinal assessment of vasculogenic potential that is 
currently lacking in traditional, static quantification methods.  Furthermore, this approach 
identified dynamic changes in network structure with a transition at 5 hours that may 
provide new mechanistic insights into vasculogenesis. 
 
Tissue Cytometry Quantitates Dividing ECFC Frequency and Localization 
Disrupted vasculogenic potential may be due to altered proliferation, survival, and/or 
migration, which are challenging phenotypes to assess in situ due to the semi-solid nature 
of the matrix used for in vitro studies.  To address this technical obstacle, 
immunofluorescence methods were developed to evaluate ECFC proliferation and 
migration during network formation.  Initially, to enhance visualization of key cellular 
components (i.e. cytoskeleton and nucleus), ECFC networks were fixed, permeabilized, 
and stained with anti-alpha tubulin and NucBlue for high-resolution imaging using confocal 
microscopy.  Interestingly, dividing ECFCs were observed in both nodes and branches 
(Figure 11A).  To achieve a comprehensive analysis of ECFC proliferation the 
immunofluorescence imaging technique was expanded to include the entire network, 
allowing for quantitation of the total number of dividing cells as well as their frequency and 
localization within the network structure (Figure 11B). 
 
To quantitate the frequency and localization of dividing ECFCs, a tissue cytometry (TC) 
software was developed.  The TC software was adapted from a broad Volumetric Tissue 
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Exploration and Analysis approach that was developed to quantitate cells associated with 
spatial parameters in 3D image volumes [123].  In the TC application, tubulin 
immunofluorescence generates a Euclidean distance map, which represents network 
structure width (Figure 12A).  TC was programmed to recognize mitotic cells based on 
high NucBlue intensity.  The distance map, in combination with NucBlue intensity, allows 
for identification of mitotic cells localized within a branch (thin <60 pixels) or node (thick 
>60 pixels, Figure 12A Insets 1 and 2).  TC allows for ‘gating’ on specific cell populations 
within a sample based on localization and NucBlue fluorescence.  Using this strategy, 
gates were applied to differentiate ECFCs located in both branch (Gate 1) and node 
regions of the network (Gate 2) (Figure 12A). 
 
The TC methodology was validated across three days using multiple ECFC samples 
(Figure 12B).  Imaging the entire structure enabled quantitation of all cells comprising the 
structure, not just those undergoing mitosis.  Whole-well analysis confirmed visual 
observation that approximately 75% of all network cells are in the nodes.  Additionally, 
around 75% of dividing cells are also localized to nodes (Figure 12B).  Thus, both nodes 
and branches have an equal propensity for cell division since total cell number is predictive 
of cell division.  Although the overall percentages observed in this analysis were not 
surprising, the high consistency across samples and experimental days was unexpected 
for this type of cell organization measure.  Importantly, these analyses were conducted on 
entire wells, enabling simultaneous, large-scale quantitation of thousands of cells in situ 
across the whole network. 
 
FIJI TrackMate Assesses ECFC Motility at the Single Cell Level 
To assess ECFC motility kinetics, a time-lapse imaging approach was established to track 
cell movement during in vitro vasculogenesis.  A baculoviral delivery system labeled 
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ECFC nuclei with green fluorescent protein (GFP) to allow for immunofluorescence image 
capture (Figure 13A).  Fluorescence imaging of punctate GFP signal enabled FIJI 
TrackMate to more easily identify and track individual cells (Figure 13B-C) [126].   Using 
this approach, three parameters of motility were assessed: including displacement, mean 
speed, and maximum speed.  Cumulative cell movement over the time-course is 
summarized as tracks representing individual cell displacement or speed (Figure 13D-
F).  To determine whether observed phenomenon was the result of differences in cell 
plating numbers, cell counts were generated using TrackMate.  Importantly, cell numbers 
were equivalent in Phase 1 (p=0.75) and Phase 2 (p=0.28).  Equal cell numbers at the 
first time point in Phase 1 confirms similar plating. Equivalent cell numbers at the beginning 
of Phase 2 (5h) suggests that proliferation and apoptosis are unlikely contributing to 
alterations in total cell number after five hours of formation. 
 
Qualitatively, individual cells assemble into primitive network structures in Phase 1, while 
more coordinated cell movements are observed in Phase 2.  Coordinated movement in 
Phase 2 is speculated to be the result of increased ECFC proximity, as cells are already 
comprising larger network structures during the second phase of formation.   In Phase 1, 
ECFCs exhibit increased displacement and speed compared to ECFCs in Phase 2 
(p=0.0001 and p=0.0002, respectively), suggesting that greater cell movement occurs in 
early network formation. Linear models were generated to determine if mean ECFC 
motility in Phase 1 is maintained in Phase 2.  Assessments using linear models indicate 
that the amount of displacement, mean speed, and maximum speed are all positively 
correlated between Phase 1 and Phase 2 (Table 3).  These analyses confirm that samples 
with greater displacement and speed in Phase 1 continue to exhibit higher displacement 
and speed in Phase 2.  Overall, all parameters of motility, including speed and 
displacement, positively correlates with the other parameters (Table 4; all p-values 
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<0.05).  Positive correlations between displacement and speed demonstrate that faster 
moving ECFCs also move farther.  This observation further suggests that ECFC 
movement is coordinated during network formation. 
 
Data Integration to Enhance Mechanistic Insights of Vasculogenesis 
KAV, TC, and motility assays assess ECFC function within the same context of network 
formation.  The power of this approach is the identification of correlated phenotypes that 
promote disrupted ECFC vasculogenic function and the potential discovery of 
mechanisms involved.  Correlating TC data (Figure 12) with KAV data (Figure 9) revealed 
that ECFC samples with increased cell division in branches formed fewer closed networks 
(r= -0.50, p=0.048). KAV also determined that some ECFC samples achieved maximal 
network number quickly while other samples displayed delayed maximal network 
formation. Therefore, to assess whether localized cell division impacted the rate of 
network formation the time to maximum networks was analyzed.  ECFCs with increased 
branch division reached maximal networks more quickly than samples with lower branch 
division (r= -0.51, p=0.044).  These data suggest that increased branch division and faster 
network formation result in an overall reduction in total network number.  In addition, 
associations were discovered between KAV and motility data.  Decreased ECFC 
displacement and mean speed in Phase 1 were associated with a higher branch to node 
ratio (r= -0.85, p=0.039 and r= -0.64, p=0.035, respectively).  Similarly, ECFCs with 
reduced displacement in Phase 2 also had a higher ratio of branches to nodes, though 
not statistically significant (r= -0.27, p=0.11).  Importantly, these results indicate that 
ECFCs that move a shorter distance or at a slower speed have higher ratios of branches 
to nodes, which is indicative of reduced network connectivity.  Overall, these observations 
guided subsequent studies outlined in the second aim to determine how intrauterine 
exposure to maternal T2DM alters ECFC vasculogenesis.  
   54 
Figures (8-13) and Table 3 
Figure 8. Kinetic Analysis of Vasculogenesis Produces Skeleton and Mask Renditions 
from Phase Contrast Images 
 
Images of ECFC network formation were captured every 15 minutes for 15 hours by phase 
contrast microscopy.  Representative phase contrast images at 5-hour increments, 
starting at the time of plating (0h), are shown.  The phase contrast images were analyzed 
using KAV to produce both “skeleton” and “mask” renditions of the network structure.  The 
scale bar represents 500 µm.  Videos showing the phase, skeleton, and mask renditions 
from all time points analyzed can be found at the following website 
http://ajpcell.physiology.org/content/312/4/C446.figures-only [133]. 
  
   55 
Figure 9. KAV Quantitates Network Metrics 
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Figure 9 continued: 
 
Mean data of 8 parameters of network structure are illustrated for 10 ECFC samples from 
uncomplicated pregnancies.  Data were quantitated using the newly developed KAV FIJI 
plugin over a 15 hour period.  Magnified regions of “mask” are depicted for the top four 
graphs.  The parameter analyzed in the corresponding line graphs below is highlighted in 
gray.  Line graphs for the following measured parameters are shown: closed networks, 
network area, nodes, branches, total branch length, triple-branched nodes, and quad-
branches nodes.  The ratio of branches to nodes, a calculated parameter, is also shown.  
The line graphs represent the mean data (± SEM) for 10 separate patient samples from 
uncomplicated (UC) pregnancies. 
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Figure 10. Validation of KAV Quantification 
 
 
 
A) To determine day-to-day variation of the assay design, KAV analysis was run for a 
single ECFC sample on 3 different days.  Data shown represent mean ± SD.  B) 
Coefficient of variation (%) is shown for the data in Panel A.  C-E) To validate the KAV 
software, manual scoring of network formation was compared with data generated by KAV 
for two individual ECFC samples on 4 different experimental days.  C-D) The number of 
Closed Networks and Nodes was no different between KAV and manual scoring.  E) The 
number of branches detected was significantly increased when using KAV compared to 
manual counting for both samples (*p<0.05).  Data are shown as mean ± SD.  
B A 
C D 
E 
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Figure 11. ECFCs Undergo Proliferation During Network Formation. 
 
 
 
A) ECFCs were plated on Matrigel for 5 hours, then fixed and stained for α-tubulin (gray) 
and NucBlue (cyan).  Representative photomicrographs of dividing cells in a node and 
branch are shown. The scale bar represents 30 µm.  B) The immunofluorescence staining 
and imaging protocols were scaled-up to include entire µ-wells.  The scale bar represents 
500µm).  
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Figure 12. Tissue Cytometry Quantifies the Frequency and Localization of Proliferating 
ECFCs on Matrigel 
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Figure 12 continued: 
 
A) Tissue cytometry (TC) analysis generated an overlay based on alpha-tubulin 
immunofluorescence, which was used to quantitate network width and discriminate 
between node and branch structures.  Mitotic cells, highlighted in red, were in branches 
(Inset 1) and nodes (Inset 2).  TC integrated network width and NucBlue fluorescence 
intensity to generate scatter plots that included all cells detected in the network (n=4733 
cells).  Gating identified mitotic cells within branches (Gate 1) and nodes (Gate 2).  Scale 
bars represent 500µm (left and middle panels) and 50µm (Inset 1).  B) Percent of total 
ECFCs (left graph) and percent of mitotic ECFCs (right graph) located in nodes or 
branches was determined by TC for 3 independent ECFC samples on 3 days (S1 = sample 
1, S2 = sample 2, S3 = sample 3).  Individual points represent data from different days. 
Mean ± SD is shown.  
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Figure 13. Assessment of ECFC Motility During Network Formation Using FIJI TrackMate 
 
 
 
A) Representative photomicrograph of nuclear GFP labelled ECFCs immediately following 
plating on Matrigel.  GFP fluorescence is shown in gray.  B) GFP signal was used to 
segment individual ECFCs in TrackMate.  ECFCs identified by the system are highlighted 
in green circles.  C) The series of fluorescence images acquired over time were analyzed 
as stacks using FIJI TrackMate.  TrackMate produces paths, shown in green, 
representative of total cell movement over the imaging interval (10 hours shown).  D-F) 
Individual ECFC paths are color-coded by the software based on variables such as (D) 
displacement, (E) maximum speed, and (F) mean speed.  The color scales indicate the 
displacement or speed ranges, with high values depicted by orange/red, and low values 
represented by blue.  The scale bar represents 500µm.  Videos showing ECFC 
displacement at all time points analyzed can be found at the following website 
http://ajpcell.physiology.org/content/312/4/C446.figures-only [133]. 
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Table 3. Phase 1 and 2 Motility Parameters 
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Aim 2: To identify novel phenotypic differences in ECFC vasculogenesis following 
exposure to intrauterine diabetes. 
 
ECFCs from Diabetic Pregnancies Exhibit Altered Network Formation Kinetics 
After establishing that KAV enabled advanced assessments of ECFC function, KAV was 
applied to ECFCs exposed to maternal T2DM in utero to further elucidate potential 
functional deficits [79].  KAV demonstrated that the complexity of network structures is 
qualitatively and quantitatively different between ECFCs from uncomplicated (UC) and 
T2DM pregnancies (Figure 14).  Qualitatively, ECFCs from T2DM pregnancies form fewer 
closed networks and have larger network areas compared to ECFCs from uncomplicated 
pregnancies (Figure 14). Although gross qualitative differences in network structure are 
visible around 10 hours post-plating, KAV analysis was performed to achieve a more 
accurate and quantitative measure of differences in network formation.  Qualitative 
observations were confirmed by quantitative KAV analyses (Figure 15).  In addition to 
confirming differences in closed network number and network area, reductions in more 
subtle phenotypes, such as total nodes and total branches, were also identified by KAV 
for T2DM-exposed ECFCs (Figure 15).  Additionally, despite evidence of qualitative 
differences at 10 hours post-plating, KAV analysis elucidated that significant differences 
in many of the structural phenotypes occur much earlier than 10 hours post-plating.  For 
example, T2DM-exposed ECFCs don’t form the same number of closed networks initially, 
as indicated by a lower peak in the closed network graph (Figure 15).  Therefore, 
differences in network structure are attributable, at least in part, to impairment in the early 
stages of formation. 
 
Decreased network stability, or increased “broken” branch connections, was also 
observed in T2DM-exposed ECFC networks during Phase 2.  Quantitation by KAV 
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confirmed that the ratio of branches to nodes, a connectivity measure, is increased in 
T2DM-exposed ECFCs, with the greatest differences occurring in Phase 2.  This 
observation suggests that not only do ECFCs from T2DM pregnancies form fewer 
networks in Phase 1, but that the network connections formed are not maintained.  For 
example, UC ECFC samples exhibited the highest branch to node ratio in Phase 1, just 
prior to maximal network formation. Conversely, ECFCs from T2DM pregnancies achieved 
maximal branch to node ratio more frequently in Phase 2 (p=0.005), suggesting a higher 
frequency of broken connections and condensing networks. 
 
Despite differences in several structural phenotypes, ECFCs from T2DM pregnancies still 
exhibit a bi-phasic pattern of network formation.  Like ECFCs from UC pregnancies, T2DM 
ECFCs undergo two phases of formation with a change occurring around 5 hours post-
plating.  Although the bi-phasic pattern of formation is maintained, KAV analysis identified 
clear differences in sample variability of individual ECFC samples from uncomplicated and 
T2DM pregnancies.  ECFCs from uncomplicated pregnancies exhibit smaller variability 
across time (Figure 15 black lines).  However, greater variation was detected in ECFCs 
from T2DM samples (Figure 15 gray lines).  Importantly, increased variability in T2DM 
ECFC function has been observed in numerous other assays as well and is likely 
attributable to increased patient heterogeneity [79]. 
 
To rigorously evaluate alterations in network formation for T2DM samples, estimated 
differences between time-lapse data were calculated (Figure 15).  Statistically significant 
differences exist between uncomplicated and T2DM groups when the estimated difference 
(± the 95% confidence limit, CI) does not cross the reference line (y=0).  These analyses 
indicate that for most of the 15-hour time course, significant differences were detected 
between uncomplicated and T2DM data in all KAV parameters.  Similar to qualitative 
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observations, the greatest difference between the curves (furthest point from reference 
line) for network area and branch to node ratio occurs in Phase 2.  Total closed networks, 
nodes, and branches initially peak near 5 hours and then level off, suggesting that 
differences in KAV parameters are phase-specific.  Together these results confirm that 
T2DM-exposed ECFCs form fewer closed networks, nodes, and branches, but develop 
larger network areas and an increased branch to node ratio compared to ECFCs from 
uncomplicated pregnancies. 
 
Diabetes Exposure Does Not Alter ECFC Proliferation During Network Formation 
To begin to identify underlying mechanisms contributing to the dramatic differences in 
network structure between ECFC samples from uncomplicated and T2DM pregnancies, 
proliferation was assessed.  First, ECFC proliferation was evaluated in the context of 
network formation.  After establishing the TC method to assess the frequency and 
localization of dividing cells on Matrigel, proliferation of ECFCs from T2DM pregnancies 
was assessed.  A 5-hour time point was chosen based on KAV results indicating the time 
for maximal closed networks (Figure 15).  TC analysis revealed that most ECFCs (~75% 
of all cells), including dividing and non-dividing, were localized in nodes in both 
experimental groups (Figure 16).  ECFCs from uncomplicated and T2DM pregnancies 
divided at similar rates overall (UC 4.1% ± 2.4, and T2DM 4.5% ± 2.8%, n=9 UC and n=7 
T2DM).  Additionally, dividing ECFCs in both groups were primarily located within nodes 
(75%) compared to branches (25%), indicating an equal propensity to divide irrespective 
of network location.  Unlike KAV analysis, sample variability was similar in both the UC 
and T2DM groups in this assay.  One outlier was observed in the number of dividing cells 
in the T2DM group.  Overall, however, there were no differences between the two sample 
groups. 
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ECFC proliferation was also assessed prior to plating on Matrigel using flow cytometric 
approaches. Overall, approximately 2-2.5% of ECFCs were undergoing division on 
collagen prior to plating (Figure 17).  Similar to TC data, ECFC proliferation was not 
different between T2DM and uncomplicated samples as determined by flow cytometry 
(n=9 UC, n=9 T2DM, p=0.35).  Thus, neither ECFC localization nor intrauterine T2DM 
exposure alters the likelihood of ECFCs to divide on collagen or after 5 hours on Matrigel.  
These measures of proliferation are acute in nature, capturing only a brief period of time.  
Therefore, to assess ECFC clonogenic potential, single cell assays were conducted on 
cells from uncomplicated and T2DM pregnancies. 
 
ECFCs from T2DM Pregnancies have Altered Clonogenicity 
Single cell assays, where ECFCs are FACS sorted and cultured for two weeks prior to 
colony size quantification, were conducted to assess ECFC clonogenicity.  Colony size is 
indicative of the ability of a single cell to proliferate and differentiate into additional cells, 
and is, therefore, a direct measure of clonogenic potential [31].  Similar to the well-
established hierarchies of hematopoietic progenitor cells, ECFCs can be distinguished by 
clonogenic and growth characteristics [134].  High proliferative potential ECFCs (HPP-
ECFCs) have high clonogenic capacity and proliferative potential, and can give rise to 
colonies with over 2000 cells after two weeks in culture.  Importantly, HPP-ECFCs form 
secondary and tertiary colonies upon re-plating and give rise to all cell types in the 
hierarchy, including other HPP-ECFCs [31].  Next in the hierarchy are low-proliferative 
potential ECFCs (LPP-ECFCs).  LPP-ECFCs form colonies containing 50-2000 cells after 
two weeks in culture, however, upon re-plating are unable to form secondary LPP-ECFC 
colonies.  Third in the hierarchy are cells that give rise to endothelial cell clusters, which 
are colonies containing 2-50 cells.  Cells comprising endothelial cell clusters are not able 
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to be re-plated into additional colonies, and are, therefore, considered to be more mature, 
differentiated cells. 
 
In the single cell assay, ECFCs from T2DM pregnancies form no HPP-ECFC colonies and 
significantly fewer LPP-ECFC colonies compared to ECFCs from uncomplicated 
pregnancies (Figure 18). Conversely, a higher percentage of T2DM-exposed ECFCs 
maintain individual, or single cell colonies after two weeks in culture.  Previously, this 
phenotype was described as representing a differentiated endothelial cell.  Therefore, 
ECFCs from T2DM pregnancies have reduced clonogenic potential compared to 
uncomplicated controls.  Future studies aimed at identifying markers of ECFC clonogenic 
potential would provide an opportunity to determine if and how clonogenicity impacts 
ECFC vasculogenesis. 
 
ECFC Motility is Not Altered Following Maternal T2DM Exposure in utero 
Based on video microscopy and KAV analysis, it is evident that ECFC network formation 
is a highly dynamic process involving numerous cellular processes.  One process that 
stood out from the video analyses was cell movement as the ECFCs migrated to form 
network structures.  Therefore, ECFC movement was assessed in ECFCs from 
uncomplicated and T2DM pregnancies to determine if alterations in migratory ability 
contributed to differences in network structure identified by KAV (Figure 19).  ECFC 
movement during Phase 1 and Phase 2 was assessed using FIJI TrackMate as described 
in Figure 13.  ECFC samples from uncomplicated and T2DM pregnancies were analyzed 
to determine if alterations in displacement, mean speed, or maximum speed could be 
underlying observed differences in network formation kinetics.  TrackMate identified and 
analyzed a similar number of tracks for both the uncomplicated and T2DM groups in Phase 
1 and Phase 2 (p=0.79 and p=0.23 respectively).  An equal number of ECFCs identified 
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in Phase 1 confirms equal plating densities between sample groups.  Equivalent track 
numbers in Phase 2 also suggests similar proliferation, as was observed in Figure 16, as 
well as survival between experimental groups. Moreover, the number of individual ECFCs 
analyzed between the uncomplicated and T2DM groups were comparable.  Of the three 
parameters evaluated, including displacement, mean speed, and maximum speed, each 
parameter positively correlated with the other two parameters in the uncomplicated as well 
as T2DM-exposed ECFCs (Figure 19 and Table 3; all p-values <0.05).  The positive 
associations between the motility parameters was also consistent between Phase 1 and 
Phase 2 for both groups.  Interestingly, the correlation coefficients (r) were consistent 
across sample groups and phases, suggesting that displacement, mean speed, and 
maximum speed have similar associations in all scenarios evaluated.  These observations 
confirm that ECFCs that move faster also move farther on average compared to ECFCs 
with slower mean and maximum speed.  In addition, intrauterine exposure to T2DM does 
not alter the positive correlations between the three motility variables tested, suggesting 
that coordinated cell movements are maintained in ECFCs from T2DM pregnancies. 
 
Overall, ECFC motility in the uncomplicated and T2DM groups was heterogeneous.  Some 
ECFCs exhibited decreased motility, as indicated by reduced displacement (Figure 
20A).  However, this phenotype was not consistently representative of a single clinical 
group.  Following statistical analysis, no differences were detected in displacement, mean 
speed, or max speed between the uncomplicated and T2DM groups in Phase 1 or Phase 
2 as indicated by nearly complete overlap of the histograms (Figure 20B).  Therefore, 
alterations in ECFC motility are not responsible for the observed structural differences in 
ECFC network formation resulting from intrauterine T2DM exposure. 
 
   69 
Clinical Data Provide Unique Translational Insights 
The combination of using the primary human patient samples and having access to clinical 
measurements provides a unique opportunity for translational insight.  Both maternal and 
infant clinical data were assessed with an emphasis on values that may reflect the severity 
of diabetes during gestation, such as maternal hemoglobin A1c.  Two T2DM ECFC 
samples (T2DM 2 and T2DM 3) were obtained from pregnancies with highly elevated 
hemoglobin A1c (> 11), indicating poor glucose control compared to normal levels which 
are less than 5 (Table 1).  These two ECFC samples, especially T2DM 3, had exacerbated 
KAV phenotypes, including a reduced number of closed networks and an increased ratio 
of branches to nodes, compared to the T2DM average of all 10 samples (Figure 21A).  
Additionally, motility analyses showed that T2DM 3 had reduced displacement in both 
Phase 1 and Phase 2 compared to a representative UC sample, as indicated by shortened 
tracks from FIJI TrackMate analysis (Figure 21B).  Together, these observations suggest 
that poor glycemic control induces change at the cellular level, which can be studied in 
vitro using analyses such as KAV.  Thus, KAV measurements may correlate with the 
severity of T2DM exposure in utero.  Testing additional samples, including those 
representing a wide range of diabetes severity, would further support this initial 
observation. 
 
Modeling Differences in Uncomplicated and T2DM Network Formation 
After performing several assessments of ECFC network formation, a few phenotypes were 
identified that appear to represent the primary differences between sample groups.  The 
ratio of branches to nodes, a novel phenotype representing network connectivity, is the 
most dramatically different ECFC phenotype discovered as a result of T2DM exposure 
(Figure 15).  Importantly, unlike many of the other phenotypes analyzed using KAV, the 
ratio of branches to nodes is not a measured value, but a calculated value derived from 
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two measurements.  Therefore, to clearly model this phenotype, a method to measure 
network connectivity was developed, and is depicted in Figure 22.  When a network 
structure is highly interconnected, the number of branches and nodes produce a smaller 
ratio, such that for 26 branches and 13 nodes the ratio is 2 (Figure 22A).  Two phenomena 
can occur to increase this ratio, as observed in the T2DM ECFC samples (Figure 15).  
First, a condensation of the nodes could occur, such that total nodes, or the denominator, 
is reduced, resulting in a higher ratio.  Alternatively, the number of branches could increase 
due to breaking apart of previously stable network connections (Figure 22B).  Although it 
is possible that both phenomena are occurring in T2DM networks, based on qualitative 
observation and KAV analysis, it appears that T2DM network structures are largely 
breaking apart in Phase 2.  Breaking branch connections results in an increased branch 
to node ratio, as the number of branches (numerator) increases (Figure 22B-C).  
Qualitatively, it is clear how the number of closed networks would decrease along with an 
increase in the average area of the closed networks due to broken branch connections.  
These three structural phenotypes combine to produce an overall working model of ECFC 
network formation (Figure 22C).  In Phase 1, ECFCs from T2DM pregnancies form fewer 
closed networks initially as well as fewer nodes and branches.  Concurrent with reduced 
closed network numbers, the area network areas are larger on average.  The initial 
impairments incurred in Phase 1 are followed by reduced stability in Phase 2.  Reduced 
network stability results in fewer maintained connections and a higher ratio of branches to 
nodes.  This working model of kinetic network formation can now serve as a baseline for 
understanding mechanisms contributing to alterations in network formation.  Subsequent 
perturbations to the system can be compared to these observations to determine 
mechanisms underlying ECFC vasculogenesis.  
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Figures (14-22) and Table 4 
Figure 14. ECFCs from T2DM Pregnancies Exhibit Impaired Network Formation 
 
 
Representative phase contrast, skeleton, and mask images of ECFCs plated on Matrigel 
at 5 hour increments, starting at the time of plating (t=0), are shown.  ECFCs were obtained 
from uncomplicated pregnancies (UC) and pregnancies complicated by T2DM.  The scale 
bars represent 500 µm.  
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Figure 15. ECFCs from T2DM Pregnancies Exhibit Altered Network Formation Kinetics 
 
 
   73 
Figure 15 continued: 
 
Kinetic analysis of vasculogenesis (KAV) software quantitated closed networks, network 
areas, nodes, branches, and the ratio of total branches divided by total nodes for both UC 
(closed circles) and T2DM pregnancies (open circles).  The data illustrated represent the 
mean ± SEM of 10 separate ECFC samples from each experimental group.  Differences 
between the mean kinetic curves of the two experimental groups for each parameter are 
shown as solid black lines with the 95% confidence interval (CI) represented by dotted 
lines.  A significant difference between the curves for a specific time point is detected if 
the CI of the difference curve does not cross the reference line (y=0) at that time point. 
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Figure 16. Exposure to T2DM Does Not Alter ECFC Proliferation Five Hours into Network 
Formation  
 
 
 
Percent of total ECFCs (left graph) and percent of mitotic ECFCs (right graph) located in 
nodes or branches was determined for UC and T2DM experimental groups.  Graphs 
represent mean ± SD (individual points represent a unique ECFC sample). 
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Figure 17. ECFC Proliferation in UC and T2DM Samples is Equivalent by Flow cytometry 
 
 
 
The percentage of ECFCs undergoing proliferation (± SEM) was determined by flow 
cytometry using phosphorylated histone H3 staining.  Approximately 2-3% of cells were 
undergoing division and there was no statistical difference between cells from 
uncomplicated and T2DM pregnancies (UC n=9, T2DM n=9, p=0.35). 
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Figure 18. ECFCs from T2DM pregnanices Form Fewer LPP and HPP Colonies  
 
 
 
 
 
ECFCs from uncomplicated and T2DM pregnancies were plated in single cell assays and 
colony sizes were scored after 14 days in culture.  Colony sizes are reported as previously 
described [31,135] with a single cell (1) representing  a differentiated endothelial cell,  2-
50 cells  indicative of endothelial cell clusters, 51-2000 cell colonies representing low-
proliferative potential (LPP) ECFCs, and 2000+ cells indicative of high-proliferative 
potential (HPP) ECFCs.  ECFCs from T2DM pregnancies have a higher percentage of 
ECFCs that are differentiated and remain as single cells in culture.  T2DM ECFCs also 
form fewer LPP colonies compared to uncomplicated controls.  (n=6 for each group, **p   
0.01).  
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Figure 19. Speed and Displacement are Correlated in Phases 1 and 2 of Network 
Formation in Uncomplicated and T2DM ECFCs 
 
 
ECFC motility was assessed at the single cell level in Phases 1 and 2 for uncomplicated 
(UC) and T2DM samples.  Associations between the three motility variables assessed 
(Mean Speed, Max Speed, and Displacement) for both phases and sample groups are 
represented as dot plots. Each dot represents an individual cell.  The correlation value (r) 
and confidence intervals (CI) are shown in the bottom right corner of each graph.  All 
parameters display positive associations.  
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Table 4. Motility Parameter Correlations 
 
  
Phase 1 UC T2DM
Mean Speed vs. Max Speed 0.64 (0.634-0.6510 0.65 (0.645-0.662)
Displacement vs. Mean Speed 0.51 (0.495-0.516) 0.50 (0.486-0.509)
Displacement vs. Max Speed 0.26 (0.251-0.278) 0.25 (0.235-0.263)
Phase 2 UC T2DM
Mean Speed vs. Max Speed 0.69 (0.682-0.702) 0.67 (0.657-0.681)
Displacement vs. Mean Speed 0.46 (0.449-0.479) 0.53 (0.512-0.544)
Displacement vs. Max Speed 0.27 (0.256-0.291) 0.33 (0.306-0.345)
values: Correlation Value, r (Confidence Interval, CI)
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Figure 20. ECFCs Exhibit a Wide Range of Motility 
 
 
A 
B 
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Figure 20 continued: 
 
A) Time-lapse images of network formation were captured over 10 hours. ECFC 
displacement was assessed separately for Phase 1 (0-5 hours) and Phase 2 (5-10 hours).  
Data from 6 UC and 6 T2DM-exposed ECFC samples are shown. A colored path 
represents total displacement, with greater displacement indicated by orange/red and less 
displacement indicated in blue.  A color scale is depicted in the upper right corner of the 
Phase 1 UC Sample 1 (UC 1) photomicrograph.  The scale bar represents 500µm.  B) 
Histograms represent the frequency of ECFC displacement, mean speed, and maximum 
speed in Phases 1 and 2 for UC (black) and T2DM (red) samples.  Approximately 35,000 
individual ECFCs were analyzed for Phase 1 (n=20 samples, 10 UC and 10 T2DM), and 
20,000 individual ECFCs were analyzed for Phase 2 (n=15, 8 UC and 7 T2DM). 
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Figure 21. Maternal Patients with High Hemoglobin A1c Have Exacerbated Phenotypes 
 
 
 
A) KAV analysis was performed on ECFC samples from uncomplicated and T2DM 
pregnancies over 15 hours of network formation.  Kinetic graphs representing the number 
of Closed Networks and the ratio of Branches to Nodes are shown.  The average from 10 
uncomplicated ECFC samples (black) and the average from 10 T2DM ECFC samples is 
shown (red).  Individual T2DM ECFC samples (2 and 3) are represented by the open black 
circle and gray circle, respectively.  These samples are from mothers with high hemoglobin 
A1C levels (>11), indicating poor glucose control during gestation (Table 1).  B) The total 
displacement of individual ECFCS from UC Sample 1 and T2DM ECFC Samples 2 and 3 
are shown for Phase 1 (0-5h) and Phase 2 (5-10h).  The scale bar represents 500µm. 
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Figure 22. Schematic of Network Connectivity Models T2DM ECFC Phenotypes 
 
 
 
A) A model network structure comprised of 26 branches and 13 nodes is completely 
connected to create one continuous structure.  Due to structure continuity, even though 
each node has 3-4 branches, the ratio of branches to nodes equals 2.  B) The same 
network structure is shown, but with breaks in two branches (arrows).  No longer a 
continuous structure, the number of branches identified by KAV increases by 2, resulting 
in an increase in the branch to node ratio to 2.15.  Decreased network connectivity results 
in discontinuous structures, which increases the ratio of branches to nodes. Network 
structures not to scale. C) Representative phase contrast images from UC and T2DM 
experimental groups are shown.  In summary, our data support a model whereby in Phase 
1 T2DM samples exhibit decreased closed networks, nodes, and branches resulting in 
increased network areas.  These changes in early network formation contribute to an 
overall decrease in network stability leading to an increase in the branch to node ratio in 
Phase 2; changes indicative of decreased network connectivity.  Scale bars represent 
500µm.  
A B 
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Aim 3: To determine if increased Transgelin 1 expression in ECFCs from gestational 
diabetic pregnancies impairs vasculogenesis. 
 
GDM Exposure Increases Transgelin 1 Expression in ECFCs 
Previously, Dr. Haneline’s laboratory conducted a microarray analysis on ECFC samples 
from uncomplicated pregnancies and those complicated by GDM to identify alterations in 
fetal gene expression following exposure to GDM [83].  One gene significantly upregulated 
in GDM-exposed ECFCs was Transgelin 1 (TAGLN).  To confirm that TAGLN expression 
is increased in ECFCs from GDM pregnancies, qRT-PCR and Western blotting analyses 
were conducted (Figure 23A-B).  GDM pregnancies were separated into two groups based 
on treatment strategy, including conservative management with diet and exercise or 
pharmacologic management with insulin therapy.  While some heterogeneity in TAGLN 
levels was evident in GDM-exposed samples, TAGLN was consistently higher in the 
insulin-treated group, but not in the conservatively managed patients (Figure 23A-B).  
Therefore, ECFC samples from the insulin-treated group were used in subsequent 
functional assays. 
 
Reducing TAGLN in GDM-exposed ECFCs Enhances Vasculogenic Functions 
ECFCs from GDM pregnancies exhibit impaired network formation in vitro, forming fewer 
closed networks in Matrigel assays [79,81].  During network formation, the ability of cells 
to move in response to pro-migratory stimuli is critical.  Therefore, ECFC migration was 
assessed in samples from GDM pregnancies to determine if altered migration contributes 
to differences in network formation.  Despite heterogeneity in the migration of ECFCs from 
GDM pregnancies, the average number of migrating ECFCs was comparable to samples 
from uncomplicated pregnancies two and four hours post-plating (Figure 24).  Since 
heterogeneity was observed in both TAGLN expression and ECFC migratory abilities, 
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correlative analyses were conducted on untreated ECFC samples to determine if TAGLN 
expression was associated with ECFC migration in vitro.  Correlation analyses detected 
no associations between TAGLN expression and ECFC migration (UC n=9, GDM n=7, 
p=0.86). 
 
TAGLN is an actin binding protein that has been implicated in regulating cell migration, a 
critical step in establishing vascular networks [108,111,112].  Previously, we showed that 
ECFCs from GDM pregnancies exhibit impaired network formation [81].  Therefore, we 
hypothesized that elevated TAGLN expression in GDM-exposed ECFCs induces impaired 
network formation.  To test this hypothesis, TAGLN was reduced in ECFCs from GDM 
pregnancies using siRNA techniques.  Representative data of repeated analyses 
demonstrated TAGLN reductions of over 90% at the RNA and protein levels (Figure 25A-
B).  Importantly, TAGLN protein levels following knockdown were similar to protein levels 
observed in ECFC samples from uncomplicated pregnancies (Figure 25B).  SiRNA-
mediated reduction in TAGLN expression increased the number of closed networks 
formed by GDM-exposed ECFCs and enhanced cell migration (Figure 25C-D).  Together, 
these results suggest that reducing TAGLN in GDM-exposed ECFCs improves 
vasculogenic and migratory abilities. 
 
Surprisingly, though ECFCs from GDM pregnancies did not exhibit reduced migration 
compared to ECFCs from uncomplicated pregnancies, TAGLN reduction in GDM-exposed 
ECFCs enhanced migration.  Therefore, additional siRNA knockdown experiments were 
conducted with ECFCs from uncomplicated pregnancies, despite low TAGLN expression, 
to evaluate for improved function.  Reducing TAGLN in ECFCs from uncomplicated 
pregnancies did not alter network formation (Figure 26A).  However, decreasing TAGLN 
did increase ECFC migration in trans-well assays (Figure 26B).  Since TAGLN is less 
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abundant in ECFCs from uncomplicated pregnancies, it was not surprising that differences 
in network formation were not observed.  However, it was surprising that ECFC migration 
was significantly enhanced following TAGLN knockdown.  Consistent enhancement of 
migration in both sample groups following TAGLN knockdown suggests that TAGLN 
inhibits ECFC migration.  Discrepancy between migration and network formation results 
likely reflect differences in the functions measured by the Matrigel and trans-well assays.  
For example, the assays require different extracellular matrices, such that network 
formation is assessed on Matrigel while migration is assessed on type 1 collagen.  
Additionally, network formation involves coordinated cell movement in multiple directions, 
while the trans-well assay involves primarily unidirectional movement toward a pro-
migratory stimulus.  Therefore, future studies aimed at evaluating the impact of TAGLN 
on ECFC function using different extracellular matrices and pro-migratory stimuli would 
provide additional insight into TAGLN regulation of vasculogenesis. 
 
To obtain a detailed, kinetic readout of ECFC network formation following reduced TAGLN 
expression, KAV methods developed in Aim 1 were applied.  Skeleton and mask 
renditions of representative network structures enable qualitative comparisons (Figure 
27A).  Qualitative differences were not obvious at the early time point (4 hours), however 
8 hours after plating, differences in network structure were apparent.  Both untreated GDM 
(UT) and siControl-treated GDM ECFCs exhibit a clear reduction in the number of closed 
networks compared to siTAGLN (Figure 27A).  This qualitative observation was confirmed 
quantitatively as the number of closed networks in the siTAGLN group peaks close to 80 
networks, while the UT and siControl groups peak around 60 networks (Figure 27B).  
Importantly, the number of closed networks in the siTAGLN group remains higher 
throughout the time course compared to the other two groups.  These results confirm the 
initial Matrigel studies at a single time point in which the numbers of closed networks were 
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quantified manually (Figure 25).  A discriminating phenotype identified in Aim 2 studies 
was the ratio of branches to nodes (Figure 15), which was indicative of decreased 
connectivity in Phase 2 of network formation.  Similar to ECFCs from T2DM pregnancies, 
ECFCs from GDM pregnancies (UT and siControl) have an increased ratio of branches to 
nodes that occurs between 5 and 10 hours of formation (Figure 27B).  In contrast, the ratio 
of branches to nodes in the siTAGLN group was constant during Phase 2 suggesting 
network stability.  Another interesting observation was decreased variability in the ratio of 
branches to nodes in the siTAGLN group.  The variability in the GDM UT and siControl 
groups was much larger, which was also previously observed in ECFC samples from 
T2DM pregnancies (Figure 15).  Overall, KAV analysis confirmed previous results from 
static assays that were counted manually as well as provided a more detailed readout of 
network formation kinetics following TAGLN reduction in GDM-exposed ECFCs. 
 
Increasing TAGLN in ECFCs from Uncomplicated Pregnancies Impairs Migration and 
Network Formation  
To determine whether increased TAGLN expression was sufficient to reduce vasculogenic 
function, a lentiviral-mediated approach was used to overexpress TAGLN in ECFCs from 
uncomplicated pregnancies.  TAGLN overexpression was confirmed by Western blotting 
(Figure 28A).  Importantly, TAGLN overexpression in ECFCs from uncomplicated 
pregnancies was comparable to endogenous TAGLN levels observed in GDM-exposed 
ECFCs (Figure 28A).  Following TAGLN overexpression, trans-well and Matrigel assays 
were performed to test ECFC migratory and network-forming abilities.  Increasing TAGLN 
expression significantly reduced the number of closed networks formed by ECFCs in 
Matrigel assays (Figure 28B).  Additionally, higher levels of TAGLN reduced ECFC 
migration in trans-well migration assays (Figure 28C).  Complimentary to the results 
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obtained in the siRNA knockdown experiments, increasing TAGLN in ECFCs from 
uncomplicated pregnancies reduced ECFC migration and network formation in vitro. 
 
Previous expression analyses were conducted with ECFCs plated on type 1 collagen, the 
primary matrix used for plating and passaging.  On collagen, ECFCs proliferate to form 
monolayers, producing a cobblestone-like morphology.  However, Matrigel elicits a 
different response.  As discussed in Aims 1 and 2, ECFCs plated on Matrigel organize to 
form networks instead of monolayers [133].  Therefore, to determine if TAGLN expression 
is altered on different extracellular matrices, a novel approach was developed to isolate 
RNA from ECFCs on Matrigel to assess TAGLN expression by qRT-PCR.  Using this new 
method (described in RNA Isolation on Matrigel, Materials and Methods), it was 
determined that endogenous TAGLN expression decreased over time on Matrigel, 
compared to the baseline measurement on type 1 collagen prior to plating (Figure 29A).  
Additionally, TAGLN expression was consistently reduced in ECFCs plated for equal 
durations (10 hours) on Matrigel compared to type 1 collagen (Figure 29B).  Importantly, 
reductions in TAGLN were observed in ECFCs from uncomplicated pregnancies as well 
as those from T2DM and GDM pregnancies.  Together, these observations suggest that 
endogenous TAGLN expression is reduced in ECFCs during network formation.  However, 
despite reductions in TAGLN expression on Matrigel, these preliminary studies suggest 
that GDM-exposed ECFCs maintain higher TAGLN expression compared to an 
uncomplicated control. 
 
To obtain a comprehensive view of ECFC network formation following TAGLN 
overexpression, KAV analysis was performed.  Qualitative observations of the networks 
using the skeleton and mask renditions demonstrated differences in network structure 
(Figure 30A).  However, in contrast to siRNA studies, differences in network structure were 
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evident at the 4-hour time point (Figure 27A).  These qualitative observations were 
confirmed quantitatively by KAV (Figure 30B).  ECFCs from uncomplicated pregnancies 
[untreated (UT) and empty vector (EV) control] formed equivalent numbers of closed 
networks.  Upon overexpression of TAGLN (TAGLN OE), the number of closed networks 
peaked at a much lower number compared to controls, with reductions maintained over 
time.  As an indication of reduced connectivity, the ratio of branches to nodes increased 
in Phase 2 in the TAGLN OE group as well (Figure 30B).  Conversely, the ratio remained 
relatively constant in the uncomplicated UT and EV control groups. 
 
TAGLN Mediates Migration via Myosin Light Chain Phosphorylation in ECFCs 
We identified that TAGLN overexpression reduces ECFC migration and network 
formation, however the specific mechanism involved is unknown. In 2006, TAGLN was 
identified as a novel regulator of matrix metalloproteinase 9 (MMP9) expression [112].  
Specifically, TAGLN repressed MMP9 expression by reducing AP-1-dependent trans-
activation of the MMP9 gene through compromised ERK activation [112].  Reduced MMP9 
transcript was confirmed in cells overexpressing TAGLN, and conversely, increased 
MMP9 transcript and protein were confirmed following TAGLN knockdown [112].  MMP9 
is a type IV collagenase that cleaves extracellular matrix components, including elastin 
and type III, IV, and V collagen, to enable cell migration [136].  In addition to TAGLN 
regulation of MMP9 expression, Transgelin 2 (TAGLN2) was identified as a negative 
regulator of myosin light chain (MLC) phosphorylation via reduction of Rho GTPase 
activity [111].  MLC phosphorylation is involved in actin-myosin interactions which are 
required for actin cytoskeletal rearrangement in cell migration [137].  Although TAGLN2 
was implicated in MLC phosphorylation, this mechanism was also evaluated in ECFCs 
since TAGLN and TAGLN2 have high genomic sequence conservation, increasing the 
likelihood for similar functions.  Additionally, the previous studies outlined above were 
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conducted in different cell types.  Specifically, MMP9 data were generated in HT1080 
(human fibrosarcoma) and WI-38 (lung fibroblast) cells, while the myosin light chain data 
were obtained in human umbilical vein endothelial cells (HUVECs).  Therefore, MMP9 
expression and phosphorylation of myosin light chain were assessed in GDM-exposed 
ECFCs to determine if TAGLN regulates cell migration through a conserved mechanism 
previously identified in other cell types. 
 
At the transcript level, MMP9 expression was not detectable in ECFC samples from GDM 
or uncomplicated pregnancies, suggesting that either decreased MMP9 is not likely the 
primary mechanism by which TAGLN reduces ECFC migration, or the sensitivity of the 
assay was not sufficient to draw conclusions (UC n=6, GDM n=8).  However, at baseline, 
ECFC samples from GDM pregnancies exhibited nearly three fold more MLC 
phosphorylation compared to uncomplicated controls (Figure 31A).  To evaluate whether 
increased TAGLN promotes myosin light chain phosphorylation, TAGLN was 
overexpressed in ECFCs from uncomplicated pregnancies to similar levels as GDM-
exposed ECFCs (Figure 28A).  ECFCs from uncomplicated pregnancies overexpressing 
TAGLN had approximately 1.5-fold increase in basal phosphorylation of MLC compared 
to control (Figure 31B), with no differences in total MLC protein observed between groups.  
We speculate that the difference in the magnitude of increased MLC phosphorylation 
between GDM-exposed ECFCs and ECFCs overexpressing TAGLN may be attributable 
to additional alterations in mechanisms that regulate MLC phosphorylation as a result of 
intrauterine GDM exposure. 
 
Converse to TAGLN overexpression, siRNA-mediated TAGLN reduction in GDM-exposed 
ECFCs did not alter MLC phosphorylation (Figure 32).  This result was surprising since 
increased MLC phosphorylation was observed in ECFCs overexpressing TAGLN.  One 
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possibility is that the timing of analysis is not appropriate and alterations in MLC 
phosphorylation were missed.  Therefore, additional time course studies could evaluate 
the effect of knockdown duration on MLC phosphorylation.  Additionally, it is quite possible 
that siRNA-mediated reductions in TAGLN are not complete (100%), such that residual 
TAGLN is sufficient to maintain MLC phosphorylation.  In previous studies, phenotypic 
differences in GDM-exposed ECFCs were enhanced under conditions of stress, such as 
serum starvation or exposure to hyperglycemia [81].  Therefore, it is possible that stress 
conditions, such as ionomycin treatment which increases MLC phosphorylation, could 
enhance differences in MLC phosphorylation following TAGLN knockdown.  Future 
studies that evaluate the effects of timing and stress conditions on MLC phosphorylation 
following TAGLN knockdown would help to confirm the initial observations presented in 
this work.  However, since increases in MLC phosphorylation were observed in both GDM 
and TAGLN-overexpressing ECFCs, additional functional studies were conducted to 
determine if MLC regulation was involved in TAGLN-mediated dysfunction. 
 
Myosin light chain kinase (MLCK) directly phosphorylates myosin light chain (Figure 33) 
[138,139].  Conversely, a myosin light chain phosphatase complex (MLPC), comprised of 
three subunits, de-phosphorylates myosin light chain.  The MLPC is inactivated by Rho 
kinase, which phosphorylates one of the MLPC subunits [138,139].  Compound Y27632 
inhibits Rho kinase, resulting in reduced MLPC phosphorylation, increased MLPC activity, 
and decreased MLC phosphorylation (Figure 33).  To evaluate whether decreased MLC 
phosphorylation induces increased ECFC migration, an approach using the Rho kinase 
inhibitor Y27632 to reduce MLC phosphorylation was developed (Figure 33).  ECFCs 
treated with Y27632 had reduced MLC phosphorylation (Figure 34).  Guided by previous 
studies in the literature, Y27532 inhibitor treatment conditions were optimized for both 
timing and dose [140,141]. Following optimization, a concentration of 0.1M Y27632 was 
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added to cell suspensions just prior to plating in trans-wells to reduce, but not totally 
deplete, MLC phosphorylation in GDM-exposed ECFC.  To determine if reducing MLC 
phosphorylation improved ECFC function, migration assays were performed following 
inhibitor treatment.  Although differences were not observed in ECFCs from uncomplicated 
pregnancies, GDM-exposed ECFCs treated with the Rho kinase inhibitor demonstrated 
increased migration (Figure 35).  This observation was expected, since ECFCs from GDM 
pregnancies have elevated MLC phosphorylation compared to uncomplicated controls.  
Similarly, Y27632-mediated Rho kinase inhibition rescued migration of ECFCs 
overexpressing TAGLN (Figure 35).  Thus, reducing the TAGLN-mediated increase in 
MLC phosphorylation was sufficient to rescue impairments in ECFC migration.  Based on 
these data, additional studies are warranted to evaluate the effect of reducing TAGLN-
mediated MLC phosphorylation on ECFC vasculogenesis. 
 
TAGLN Does Not Alter Total Filamentous Actin Levels  
In response to laminar flow, endothelial cells rearrange their cytoskeleton to align in the 
direction of the flow [110].  This well-characterized phenomenon is indicative of the ability 
of endothelial cells to respond successfully to environmental cues.  One primary 
mechanism involved in endothelial cell alignment to shear stress is actin cytoskeletal 
rearrangement.  TAGLN is an actin binding protein that contributes to the formation and 
stabilization of filamentous actin (F-actin) bundles or stress fibers [106–109].  Therefore, 
to determine whether TAGLN overexpression increases total F-actin, relative amounts of 
globular (G-actin) and F-actin were measured in ECFCs following TAGLN overexpression 
using two different approaches.  First, G-actin and F-actin protein levels were quantified 
using a centrifugation technique followed by western blotting (Figure 36).  Using this 
approach, differences in total F-actin protein were not observed in TAGLN overexpressing 
cells compared to empty vector controls (EV control).  This observation suggests that 
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TAGLN does not increase the amount of F-actin in the cell.  Additionally, an intracellular, 
flow cytometric technique was used to evaluate TAGLN overexpression and quantify F-
actin in ECFCs.  To determine the sensitivity of the assay and the range of detection, initial 
studies using Cytochalasin D were performed.  Cytochalasin D was chosen as it inhibits 
actin polymerization as well as induces de-polymerization of actin filaments [142].  ECFC 
treatment with Cytochalasin D significantly reduced the amount of F-actin detected by flow 
cytometry (Figure 37A).  Importantly, while optimizing the experimental approach, an 
inverse relationship was identified between the number of cells stained and the amount of 
F-actin and TAGLN probes detected (Figure 37B).  Taking this data into account, 
subsequent studies were conducted using stringent cell counting techniques.  Several EV 
control samples were used to test assay variability and reproducibility.  Consistent 
intracellular TAGLN and F-actin levels were observed across EV control samples (Figure 
37C).  Finally, upon comparison of EV control and TAGLN OE samples, TAGLN was 
increased, however no differences in F-actin were observed between sample groups 
(Figure 37D).  These results are consistent with data from the centrifugation assay (Figure 
36).  TAGLN overexpression did not alter total F-actin in ECFCs from uncomplicated 
pregnancies.  Although the total amount of F-actin is unchanged following TAGLN 
overexpression, it is still unclear whether TAGLN expression alters organization of F-actin, 
such as F-actin bundling into stress fibers.  Therefore, future studies to assess the amount 
of F-actin bundling may clarify the mechanism by which TAGLN expression alters ECFC 
migration. 
 
TAGLN Regulates ECFC Response to Laminar Flow 
Previous studies reported co-localization of TAGLN and F-actin using 
immunofluorescence techniques [106,107].  Therefore, confocal microscopy was used to 
confirm localization of TAGLN and F-actin in ECFCs.  Using confocal microscopy, it was 
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evident that TAGLN and F-actin primarily co-localize within the cell (Figure 38).  This 
observation is not surprising as TAGLN has a conserved actin binding domain.  However, 
co-localization in ECFCs had not been previously reported.  Following confirmation of co-
localization, shear assays were conducted to determine if TAGLN impacts the ability of 
ECFCs to align in response to flow, a conserved endothelial cell phenotype [110]. 
 
To determine whether ECFCs overexpressing TAGLN align in the direction of laminar flow, 
ECFCs were transduced with either empty vector control (EV control) or TAGLN-
containing (TAGLN OE) lentivirus.  Following transduction, ECFCs were either maintained 
in static culture, or subjected to seven hours of flow as previously described [127,128]. 
Glass slides from static culture and the flow chamber were fixed and stained for TAGLN, 
F-actin, and NucBlue.  Fluorescence images were captured from eight field-matched 
locations on the slide, and the ImageJ Directionality Plug-in was used to analyze ECFC 
alignment based on the F-actin immunofluorescence images (Figure 39) [130].  Based on 
the direction of the flow, proper cell alignment should result in a mean angle slightly greater 
than zero (*arrows Figure 39A). Qualitatively, ECFCs transduced with EV control lentivirus 
under static culture conditions exhibited slight alignment at baseline (Figure 39A).  
However, following exposure to seven hours of laminar flow, alignment of EV control cells 
increased as evidenced by near complete unidirectional F-actin filament alignment (Figure 
39A).  Upon overexpression of TAGLN, ECFCs did not have coordinated alignment at 
baseline, but appeared random and disjoined in relation to neighboring cells (Figure 39A).  
Following exposure to laminar flow, TAGLN OE ECFC attempt at alignment was evident, 
but often the angle of alignment was not clearly in the direction of the flow (Figure 39A).  
Quantitation of cell alignment using the ImageJ Directionality Plug-in supported qualitative 
observations. Blue histograms generated by the Plug-in represent the distribution of the 
angles detected within the corresponding F-actin fluorescence images in Panel A (Figure 
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39B).  A Gaussian distribution, like in the EV control +Flow histogram, indicates consistent 
cell alignment.  Alternatively, flat histograms indicate randomized cell alignment.  
Individual image data for each condition were combined to produce single graphics of 
overlaid, individual histograms (Figure 39C).  This analytic approach enabled visualization 
of mean angle variation and distribution.  Interestingly, ECFCs transduced with empty 
vector control lentivirus (EV control) exhibited partial alignment even in the absence of 
flow, as indicated by overlapping histograms (Figure 39C).  Following seven hours of 
laminar flow, ECFCs transduced with EV control lentivirus aligned in the direction of the 
flow as indicated by greater histogram overlap with histogram peaks at angles slightly 
greater than zero (Figure 39C).  Conversely, TAGLN overexpressing cells (TAGLN OE) 
displayed greater variability in cell alignment at baseline, indicated by non-overlapping 
histograms with random peaks indicative of varying alignment angles (Figure 39C).  This 
finding was surprising because initial speculation was that differences in cell alignment 
would be enhanced and identified under conditions of shear stress, or flow.  However, 
qualitative observations of TAGLN immunofluorescence images suggest that increased 
baseline heterogeneity could reflect heterogeneity in TAGLE overexpression across the 
cell population analyzed.  Following exposure to seven hours of laminar flow, ECFCs 
overexpressing TAGLN attempted to align, but were unable to align to the same extent as 
the ECFCs transduced with EV control.  Partial alignment is indicated by flattened 
histograms located at angles slightly greater than zero as well as histograms with peaks 
at angles less than zero (Figure 39C).  Overall, the angle variance, or spread in mean 
angle distribution, was low in EV control samples which consistently align in the direction 
of the flow (Figure 39D).  ECFCs overexpressing TAGLN attempt to align, but don’t 
achieve an arrangement as uniform as EV control samples, which results in a lower mean 
angle and greater angle variance (Figure 39D).  Analysis by Two-way ANOVA confirmed 
that the mean angle of cell alignment is impacted by TAGLN expression under basal and 
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flow conditions (p=0.0037).  Additionally, flow significantly impacts angle variance, with a 
466-unit (se=120) reduction in the variance of mean angles following flow (p=0.0002).  
However, angle variance is also significantly associated with TAGLN expression, such 
that the variance is increased 416-units (se=120) in the TAGLN OE group compared to 
the EV control group (p=0.0009).  Thus, ECFCs effectively respond to shear stress by 
aligning to the direction of the flow.  However, TAGLN overexpression alters basal and 
flow-mediated cell alignment. 
 
ECFCs from Uncomplicated and GDM Pregnancies Align to Laminar Flow  
Given that GDM-exposed ECFCs exhibit increased TAGLN expression and ECFCs 
overexpressing TAGLN exhibit a decreased response to laminar flow, I hypothesized that 
ECFCs from GDM pregnancies would have a decreased response to laminar flow.  
Therefore, additional assays were conducted to evaluate for differences between ECFC 
samples from uncomplicated and GDM pregnancies.  Representative photomicrographs 
of ECFCs from uncomplicated (UC) and GDM pregnancies indicate basal and flow-
induced cell alignment (Figure 40A).  Qualitatively, ECFCs from UC pregnancies exhibited 
random, uncoordinated alignment under static culture conditions (Figure 40A).  Following 
exposure to seven hours of laminar flow, ECFCs from UC pregnancies conformed to 
unidirectional alignment in the direction of the flow (Figure 40A).  GDM-exposed ECFCs 
also exhibited non-coordinated alignment under static culture conditions.  Similar to 
ECFCs from UC pregnancies, exposure to laminar flow prompted GDM-exposed ECFC 
alignment (Figure 40A).  Qualitative observations were confirmed quantitatively using the 
ImageJ Directionality Plug-In.  Single graphics depicting histograms representing data 
from nine individual image fields are shown for three UC and GDM samples (Figure 40B).  
Non-uniform alignment of ECFCs from UC pregnancies under static culture conditions 
resulted in decreased histogram overlap with mismatched peaks.  Different patterns of cell 
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alignment were evident in the individual samples tested (Figure 40B).  However, following 
exposure to laminar flow, all three UC samples displayed unidirectional alignment as 
indicated by increased histogram overlap with peaks occurring near the angle of the flow 
direction.  ECFCs from GDM pregnancies also exhibited multi-directional alignment under 
static culture conditions as indicated by histogram misalignment (Figure 40B).  Exposure 
to seven hours of laminar flow resulted in an increase in GDM-exposed ECFC alignment 
compared to static culture controls.  However, upon comparison to ECFCs from UC 
pregnancies under flow, GDM-exposed ECFCs did not appear to align to the same extent, 
as indicated by reduced histogram overlap (Figure 40B, statistical analysis performed 
below).  This observation suggests that GDM-exposed ECFCs attempted to align in 
response to shear stress, but were not as proficient as samples from UC pregnancies, 
resulting in greater variability.  Statistical analysis was conducted on the data generated 
by the Directionality Plug-in to quantitatively compare ECFC response to shear stress.  
Under static culture conditions, both UC and GDM groups exhibited similar mean angle 
values, although GDM-exposed ECFCs displayed greater mean angle heterogeneity 
indicated by larger deviation (Figure 40C).  Larger deviation in angle variance was also 
evident in GDM-exposed samples (Figure 40C).  Statistical modeling confirmed that cell 
alignment, indicated by the mean angle, was influenced by exposure to laminar flow, 
irrespective of the sample group (n=6, p=0.034).  Similarly, angle variance was impacted 
by laminar flow exposure (n=6, p=4.0e-08).  Contrary to the original hypothesis, 
intrauterine GDM exposure did not impact angle variance (UC n=3, GDM n=3, p=0.08).  
Additionally, analysis by two-way ANOVA indicated no interaction between intrauterine 
GDM exposure and laminar flow in relation to ECFC alignment (UC n=3, GDM n=3, 
p=0.07).  Although statistical differences between UC and GDM samples were not 
identified in this study, low sample size may be limiting the ability to detect differences. 
Previous functional assessments of GDM-exposed ECFCs required high sample 
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numbers, likely due to disease heterogeneity and duration.  Therefore, additional studies 
with higher sample numbers are needed to formulate conclusions. 
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Figures (23-40) 
Figure 23. TAGLN is Elevated in ECFCs from GDM Pregnancies 
 
 
 
A) RNA was isolated from ECFCs obtained from uncomplicated, GDM-diet, and GDM-
insulin controlled pregnancies. Using qRT-PCR, relative amounts of Transgelin mRNA 
were quantified and normalized to HPRT.  ECFCs from GDM-insulin pregnancies had 
significantly higher levels of Transgelin mRNA compared to samples from uncomplicated 
control pregnancies (UC n=8, GDM-diet controlled (DC) and GDM-insulin controlled (INS) 
n= 4, p=0.017).  B) A representative Western blot of repeated analyses depicting whole-
cell ECFC protein lysates from uncomplicated, GDM-DC, and GDM-INS pregnancies. The 
membrane was probed with antibodies against Transgelin 1 (TAGLN) and vinculin.  
Western blot densitometry confirmed that ECFC samples from GDM pregnancies have 
more TAGLN protein compared to uncomplicated controls (UC n=5, GDM-DC and GDM-
INS n=3, p=0.014).  
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Figure 24. Intrauterine GDM Exposure Does Not Alter ECFC Migration 
 
 
 
Trans-well migration assays were performed with ECFCs from uncomplicated (UC, black 
bars) pregnancies and pregnancies complicated with gestational diabetes mellitus (GDM, 
patterned bars).  The number of migrated cells was quantified at two and four hours post-
plating.  Results were analyzed by two-way ANOVA.  Time impacted the number of 
migrated cells (p<0.0001), but GDM did not (p=0.61).  There was no interaction between 
time and GDM by two-way ANOVA analysis (p=0.62). (UC n=6, GDM n=6) 
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Figure 25. Elevated TAGLN in GDM-exposed ECFCs is Sufficient to Impair Function 
 
 
 
 
A) TAGLN transcript levels were measured 48 hours post-transfection in three different 
ECFC samples treated with siControl or siTAGLN.  All TAGLN levels were normalized to 
HPRT.  siTAGLN values were then normalized to their corresponding siControl sample  
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Figure 25 continued: 
 
values. (n=3) B) A western blot depicting whole-cell protein lysates from untreated ECFCs 
from uncomplicated pregnancies (UC) and ECFCs from GDM pregnancies treated with 
non-specific siRNA (siControl) or TAGLN-specific siRNA (siTAGLN).  Membranes were 
probed for TAGLN and Vinculin. C) Phase contrast images of ECFC network formation on 
Matrigel 10 hours post-plating following siControl or siTAGLN treatments.  The numbers 
of closed networks formed were quantified and graphed (n=8 transfections, *p=0.019).  D) 
Trans-well migration assays were performed with ECFCs transfected with siControl or 
siTAGLN.  Photomicrographs depict migrated ECFCs stained with crystal violet.  The 
numbers of migrating cells after four hours were quantified and graphed (n=10 
transfections, *p=0.028).  
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Figure 26. Reducing TAGLN in ECFCs from Uncomplicated Pregnancies Alters Migration 
but Not Network Formation 
 
 
 
 
A) Phase contrast images of ECFC network formation on Matrigel 10 hours post-plating 
following treatment with non-specific siRNA (siControl) or TAGLN-specific siRNA 
(siTAGLN).  The numbers of closed networks were quantified and graphed with no 
differences observed between treatment groups (n=4 transfections, p=0.12).  B) Trans-
well migration assays were performed following treatment with non-specific siRNA 
(siControl) or TAGLN-specific siRNA (siTAGLN). The numbers of migrating cells after four 
hours were quantified and graphed (n=5 transfections, **p=0.005). 
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Figure 27. KAV Analysis Confirms siRNA-mediated Knockdown of TAGLN in GDM-
exposed ECFCs Rescues Network Formation 
 
 
 
A) Representative phase contrast, skeleton, and mask images of ECFC network formation 
on Matrigel at 4 and 8 hours post-plating.  ECFCs were obtained from GDM pregnancies 
and were untreated (UT) or treated with non-specific siRNA (siControl) or TAGLN-specific 
siRNA (siTAGLN).  The scale bar represents 500 µm. B) Kinetic analysis of 
vasculogenesis (KAV) software quantitated closed networks and the ratio of total branches 
divided by total nodes for UT (black), siControl (gray), and siTAGLN (white) samples.  The 
data illustrated represent the mean ± SEM of 3 separate experiments for each group. 
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Figure 28: Increasing TAGLN in Low-expressing ECFCs is Sufficient to Impair Function  
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Figure 28 continued: 
 
A) A western blot depicting whole-cell protein lysates collected on type 1 collagen from 
untreated GDM-exposed ECFCs and ECFCs from uncomplicated pregnancies 
transduced with a control lentivirus (EV control) or a TAGLN-expressing lentivirus (TAGLN 
OE).  Membranes were probed for TAGLN and Vinculin. B) Phase contrast images of 
ECFC network formation on Matrigel following transduction with either EV control or 
TAGLN OE lentivirus.  The numbers of closed networks were quantified 10 hours post-
plating and graphed (n=9 transductions, p=0.047).  C) Trans-well migration assays were 
performed with ECFCs transduced with EV control or TAGLN OE lentivirus.  
Photomicrographs depict migrated ECFCs stained with crystal violet 4 hours after plating.  
The numbers of migrating cells after four hours were quantified and graphed (n=11 
transductions, p=0.015).  
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Figure 29. TAGLN Transcript Levels are Decreased on Matrigel 
 
A) TAGLN mRNA was measured in three different ECFC samples at baseline (0h) on type 
1 collagen, and at 5, 10, and 20 hours on Matrigel (UC n=2, T2DM n=1).  TAGLN mRNA 
levels were normalized to HPRT.  Analysis by one-way ANOVA identified a difference in 
TAGLN transcript at the different time points (n=3, *p=0.0479).  B) RNA was collected 
from ECFC samples plated on type 1 collagen (black) or Matrigel matrix (gray) for 10 
hours.  TAGLN transcript levels were normalized to HPRT (mean ± SD).  Results were 
analyzed by a Two-way ANOVA (UC n=3, GDM n=6, T2DM n=3).  TAGLN expression is 
reduced on Matrigel compared to type 1 collagen (p=0.008).  
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Figure 30. KAV Analysis Confirms Impaired ECFC Vasculogenesis following TAGLN 
Overexpression 
 
 
 
 
A) Representative phase contrast, skeleton, and mask images of ECFC network formation 
on Matrigel at 4 and 8 hours post-plating.  ECFCs were obtained from uncomplicated 
pregnancies and were untreated (UT) or treated with a control lentivirus (EV control) or 
TAGLN-containing lentivirus (TAGLN OE).  The scale bar represents 500 µm. B) Kinetic 
analysis of vasculogenesis (KAV) software quantitated closed networks and the ratio of 
total branches divided by total nodes for UT (black), EV control (gray), and TAGLN OE 
(white) samples.  The data illustrated represent the mean ± SEM of 3 separate 
experiments for each group.  
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Figure 31: Myosin Light Chain Phosphorylation is Increased in ECFCs with Elevated 
TAGLN  
 
A) Two western blots depicting whole-cell protein lysates from ECFCs isolated from 
uncomplicated (UC) or GDM pregnancies. Membranes were probed with antibodies 
against phospho-myosin light chain (p-MLC), total myosin light chain (MLC), and vinculin 
(Vinc). Western blot quantification confirmed increased levels of pMLC relative to total 
myosin light chain in samples from GDM pregnancies (UC n=4, GDM n=6, **p=0.003).  B)  
A western blot depicting whole-cell protein lysates from ECFCs from uncomplicated 
pregnancies treated with control lentivirus (EV control) or lentivirus containing TAGLN 
(TAGLN OE). The membrane was probed with antibodies against phospho-myosin light 
chain (p-MLC), total myosin light chain (MLC), Transgelin (TAGLN), and vinculin (Vinc). 
Western blot quantitation confirmed increased levels of pMLC relative to total myosin light 
chain (n= 7 transductions, **p=0.002).  
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Figure. 32. Reducing TAGLN in GDM-exposed ECFCs Does Not Alter Myosin Light Chain 
Phosphorylation 
 
 
 
A) A representative western blot depicting whole-cell protein lysates from ECFCs from 
GDM pregnancies treated with non-specific siRNA (siControl) or TAGLN-specific siRNA 
(siTAGLN).  Membranes were probed for phosphorylated myosin light chain (pMLC), total 
myosin light chain (MLC), and Vinculin. B) Western blot densitometry confirmed no 
difference in myosin light chain phosphorylation following TAGLN knockdown in GDM-
exposed ECFCs (n=7, p=0.86).  
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Figure 33. Schematic Depicting Strategy to Regulate Myosin Light Chain Phosphorylation 
 
 
Myosin light chain (MLC) phosphorylation is regulated by two primary mechanisms.  First, 
myosin light chain kinase (MLCK) directly phosphorylates (black circle) MLC.  Second, a 
three-subunit myosin light chain phosphatase complex (MLPC), de-phosphorylates MLC 
when in the active (de-phosphorylated) state.  The MLPC is regulated by Rho kinase, 
which phosphorylates one of the subunits in the complex, rendering the complex inactive.  
The Y27632 inhibitor (red X) blocks Rho kinase activity, such that it is unable to render 
MLPC inactive through phosphorylation. Schematic is adapted from Ramachandran et al. 
(2011) [139].  
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Figure 34. Optimization of Rho kinase Inhibitor (Y27632) Treatment 
 
 
 
A) ECFCs from GDM pregnancies were treated with different concentrations (0-50µm) of 
a Rho kinase inhibitor (Y27632) for one hour prior to lysate collection. A western blot 
depicts phosphorylated myosin light chain (pMLC) and vinculin (Vinc).  B) ECFCs from 
GDM pregnancies were treated with either 0, 0.1, or 1.0 µM of Y27632 for one or four 
hours as shown.  A western blot depicts phosphorylated myosin light chain (pMLC), total 
myosin light chain (MLC), and vinculin (Vinc).  C) ECFCs from GDM pregnancies were 
treated with 0, 0.1, or 1.0 µM of Y27632 inhibitor in a time-course assay with treatments 
ranging from 0-120 minutes as shown.  A western blot depicts phosphorylated myosin 
light chain (pMLC), total myosin light chain (MLC), and vinculin (Vinc). 
  
A 
B 
C 
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Figure 35. Reducing Myosin Light Chain Phosphorylation Rescues ECFC Migration 
 
 
A) ECFCs from uncomplicated (UC) and GDM pregnancies were either untreated (-) or 
treated by adding 0.1M Rho kinase inhibitor Y27632 (+) to the cell suspension just prior 
to plating in trans-well assays.  After four hours, trans-wells were fixed and the number of 
migrated cells was quantified from eight randomized image fields per treatment group. 
Results were analyzed by two-way ANOVA followed by Sidak’s multiple comparison test 
(UC n=3, GDM n=6, *p=01). B) ECFCs from uncomplicated pregnancies transduced with 
control lentivirus (EV control) or a lentivirus containing TAGLN (TAGLN OE) were 
untreated (-) or treated with Rho kinase inhibitor Y27632 (+) and plated in trans-well 
assays.  After four hours, trans-wells were fixed and the number of migrated cells was 
quantified from eight randomized image fields per treatment group. Results were analyzed 
by two-way ANOVA followed by Sidak’s multiple comparison test (n=5 transductions, 
*p=0.019).  
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Figure 36. Total G-actin and F-Actin Levels are Not Different Following TAGLN 
Overexpression 
 
A western blot depicting lysates from two different ECFC samples (1-2) that were collected 
following transduction with either a control lentivirus (EV) or a lentivirus containing TAGLN 
(TAG).  Centrifugation was performed to isolate the G-actin and F-actin fractions from the 
lysates.  A western blot was performed using the processed lysates and the membrane 
was probed for Actin and Vinculin.  
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Figure 37. Flow Cytometric Analysis Confirms No Difference in F-actin following TAGLN 
Overexpression 
 
 
 
A) ECFCs from uncomplicated pregnancies were treated with DMSO (Vehicle Control, 
red) or 10M Cytochalasin D (blue) for one hour.  Following treatment, total F-actin was 
measured using flow cytometry.  Cytochalasin D-treated sample values were normalized 
to Vehicle Control and mean (peak) values are graphed (n=4, ***p=0.0009). B) Five 
different concentrations of ECFC suspensions ranging from 100,000-800,000 cells were 
stained for F-actin (left) and TAGLN (right) and analyzed by flow cytometry.  An unstained 
control (gray) is shown in the F-actin panel. C) Three different ECFC samples (1-3) were 
transduced with control lentivirus (EV) and stained for TAGLN (left) and F-actin (right).  
Graphs depict the amount of TAGLN and F-actin in all three samples.  
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Figure 37 continued: 
 
 
 
D) ECFCs from uncomplicated pregnancies were transduced with a control lentivirus (EV 
Control, red) or a lentivirus containing TAGLN (TAGLN OE, blue). Representative 
histograms are shown demonstrating the amount of TAGLN (left) and F-actin (right) in one 
ECFC sample.  Bar graphs to the right of each histogram represent mean peak values 
from three separate transduced ECFC samples. (n=11 transductions, **p=0.0029) 
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Figure 38. TAGLN Localizes to F-actin in ECFCs 
 
ECFCs from a GDM pregnancy were plated on type 1 collagen-coated glass slides and 
stained for TAGLN (red) and F-actin (green).  NucBlue was used as a nuclear stain (blue) 
and all three channels were overlaid in the fourth panel (Merge).  Images were obtained 
using confocal microscopy.  The scale bar represents 50m. 
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Figure 39. TAGLN Alters ECFC Alignment and Response to Shear Stress 
 
 
 
A) ECFCs from uncomplicated pregnancies were transduced with control lentivirus (EV 
control) or a lentivirus containing TAGLN (TAGLN OE).  Transduced ECFCs were plated 
on type 1 collagen-coated glass slides and were maintained in static culture medium (No 
Flow) or exposed to 7 hours of laminar flow (+Flow) using a custom apparatus as 
previously described [127,128].  Direction of flow is indicated by white arrows in upper 
corner of images.  Following treatment, ECFCs were fixed and stained for TAGLN (red), 
F-actin (green), and NucBlue (blue).  All three channels were overlaid in the Merged 
image.  Scale bars represent 6350m.  B) ECFC alignment was analyzed with the 
Directionality Plug-in (ImageJ). F-actin fluorescence images were used to generate the 
single, blue histograms representing angle distribution from the representative sample 
images above.  
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Figure 39 continued: 
 
 
 
 
C) Histograms representing all images for each group were combined and overlaid. D) 
Box and whisker plots representing statistical analysis completed to compare the mean 
angle and angle variance distributions between the two treatment groups (EV control and 
TAGLN OE) in the presence and absence of Flow.  
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Figure 40. ECFCs from Uncomplicated and GDM Pregnancies Align with Laminar Flow 
 
 
 
A) ECFCs from uncomplicated (UC) and GDM pregnancies were plated on type 1 
collagen-coated glass slides and were maintained in static culture medium (No Flow) or 
exposed to 7 hours of laminar flow (Flow) using a custom apparatus as previously 
described [127,128].  Direction of flow is indicated by white arrows in upper corner of 
images.  Following treatment, ECFCs were fixed and stained for TAGLN (red), F-actin 
(green), and NucBlue (blue).  All three channels were overlaid in the Merged image.  Scale 
bars represent 6350m. 
 
Figure continued on the next page.  
A 
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Figure 40 continued: 
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Figure 40 continued: 
 
B) ECFC alignment was analyzed with the Directionality Plug-in (ImageJ).  The F-actin 
fluorescence images were used to produce the histograms representing the distribution of 
angles measured within eight images for each group, which were combined and overlaid. 
C) Box and whisker plots representing statistical analysis completed to compare the mean 
angle and angle variance distributions between the two sample groups (UC and GDM) in 
the presence and absence of flow. 
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CHAPTER 4: CONCLUSION 
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Discussion 
 
The objectives of this work were to identify novel phenotypes involved in vasculogenesis 
and to investigate the molecular mechanisms altered in fetal ECFC vasculogenesis 
following in utero maternal diabetes mellitus exposure.  I made significant progress 
towards these objectives through the completion of several independent studies and the 
development of new technologies that can be applied to future studies in the field.  The 
results of these investigations are summarized under the corresponding study aims below. 
 
Aim 1: To develop innovative methods to quantitatively assess the kinetics of ECFC 
vasculogenesis in vitro. 
 
Implementation of Technological Advancements to Overcome Assay Limitations 
Advancements in imaging technology have created new challenges for image processing 
and quantitative analysis.  These challenges include managing large volumes of data and 
deriving new biologically meaningful results that are not dependent upon manual 
analyses.  Therefore, development of automated image analysis is crucial for maximizing 
information obtained from independent experiments, which in turn will provide 
opportunities for discovery of novel pathologic phenotypes.  Automation enables multi-
parametric investigation of a broad range of quantitative measures that are too difficult to 
detect manually [143–145].  Additionally, automation can increase assay sensitivity and 
reproducibility while minimizing time, labor, and bias.  In the study of vasculogenesis, 
automation of image analysis allows for greater mechanistic understanding of the 
complex, kinetic process of network formation.  Although some automated vasculogenic 
image analyses are commercially available, many technologies are cost-prohibitive for 
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large, kinetic studies [146].  Therefore, a primary limitation in the field is an open source 
platform for assessing kinetic measurements of vasculogenesis in vitro. 
 
In the Aim 1 results section, new techniques were optimized to assess the kinetics of 
ECFC function and identify correlative vasculogenic phenotypes [133].  KAV measured 
numerous structural phenotypes, identifying two phases of network formation.  The 
transition point between phases was associated with maximal network connectivity. 
Additionally, KAV calculated a novel and direct measure of connectivity, the branch to-
node-ratio.  Motility analyses determined how individual cell movement impacted network 
formation. Greater movement occurred during early network formation, and movement in 
Phase 1 directly correlated with Phase 2 movement.  Future studies that assess 
directionality of cell movement will be important to determine whether ECFCs respond to 
pro-migratory stimuli with coordinated movements. 
 
Assessment of proliferation by nuclear markers, such as histone H3 phosphorylation, is a 
standard technique.  However, assessing proliferation during network formation is novel.  
Tissue Cytometry (TC) enabled identification of distinct cell populations based on 
fluorescence and localization.  Thus, TC is an innovative and powerful tool to assess 
cellular events, such as proliferation, apoptosis, and senescence on a large-scale in 
thousands of cells.  Specifically, this technique was applied to quantitate localization of 
proliferating ECFCs within networks at a single cell resolution. TC revealed that few 
ECFCs divide (2-8%) in early network formation.  Dividing ECFCs are primarily in nodes 
where most cells reside, however ECFCs in branches are equally likely to undergo 
division.  Importantly, this TC approach could be applied to assess the frequency and 
localization of a variety of cellular events that can be fluorescently labeled during 
vasculogenesis.  Thus, the potential impact of applying this newly developed methodology 
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to unique biologic systems is yet to be realized.  Overall, the improvements to standard 
imaging and quantitation strategies outlined in Aim1 provide insight into potential 
mechanisms contributing to altered ECFC vasculogenesis and can be applied to any 
vascular system or cell type. 
 
Strengths of New Experimental Approaches 
Assessing multiple phenotypes within the same biologic system provides an opportunity 
to identify correlative phenotypes.  In our system, negative correlations were identified 
between KAV parameters and TC data.  Samples with higher branch proliferation formed 
maximal closed networks quickly, though fewer total closed networks overall.  KAV 
parameters also correlated with ECFC motility.  Specifically, ECFCs that move shorter 
distances or at slower speeds during early network formation have a higher branch to 
node ratio, or reduced connectivity.  We speculate that ECFCs that move less form fewer 
nodes, resulting in longer branches and decreased network stability.  Fewer nodes and 
decreased network stability (i.e. reduced connectivity) would result in an increased ratio 
of branches to nodes. 
 
Though in vivo models provide a more complete view of vasculogenic function [147], the 
new approaches outlined for in vitro studies are informative without being cost-prohibitive 
and can guide future in vivo studies.  A concrete example is that the ratio of branches to 
nodes is not generally evaluated.  However, it was the phenotype most strongly correlated 
with ECFC motility, and one of the most informative phenotypes in differentiating ECFC 
vasculogenic function. Based on these findings, future studies that focus on understanding 
the basis for increased branch to node ratio could be highly instructive and promote 
mechanistic insights into altered vasculogenesis.  Furthermore, the automated imaging 
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analyses reported here could be applied to in vivo models, thereby broadening the impact 
of the open source resources developed in this thesis to assess vasculogenesis. 
 
Aim 2: To identify novel phenotypic differences in ECFC vasculogenesis following 
exposure to intrauterine diabetes.   
 
Intrauterine Exposure to Maternal T2DM Alters Kinetics of Fetal ECFC Vasulogenesis  
The techniques developed here were implemented to identify how exposure to a maternal 
T2DM environment alters ECFC network formation.  These new data confirm previous 
findings that ECFCs exposed to intrauterine T2DM have impaired vasculogenesis [79].  
However, time-lapse imaging identified two phases of vasculogenesis, which was 
previously unappreciated.  KAV methodology demonstrated that ECFCs exposed to T2DM 
in utero form (Phase 1) and maintain fewer networks (Phase 2), resulting in increased 
average network areas. In T2DM ECFCs, the onset of a pathologic increase in the branch 
to node ratio in Phase 2 is speculated to indicate network instability, or an inability to 
maintain branch connections.   
 
Overall, differences in proliferation were not observed between ECFC sample groups in 
either of the two assays that measured proliferation acutely (Figures 16-17).  Additionally, 
acute ECFC proliferation is not altered on collagen or Matrigel following exposure to 
maternal T2DM in utero.  However, significant differences in ECFC clonogenic potential 
following intrauterine exposure to T2DM were identified in a more chronic, long-term 
assessment (Figure 18).  This finding suggests that the identified ECFC defect in short-
term network formation, as measured in vitro, is not secondary to altered proliferation.  
Alternatively, it is possible that current in vitro static measurements of proliferation during 
the process of vasculogenesis are insufficient to capture subtle differences in the 
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proliferation of ECFCs.  Given the observation that T2DM-exposed ECFC samples had 
no HPP-ECFCs, long-term repopulating ability is predicted to be reduced.  The 
consequences of altered repopulation capacity can’t be measured by current short-term 
measurements of vasculogenesis in vitro.  However, these results do support previous 
findings that ECFCs from T2DM pregnancies have significantly reduced vessel-forming 
ability in vivo [79].  Future studies in which associations between clonogenic capacity 
measured in vitro and vessel formation in vivo would be informative in understanding how 
functional phenotypes may be producing long-term vascular complications in offspring. 
 
Challenges of Studying Primary Human Samples 
Surprisingly, ECFC proliferation and motility were not different between the uncomplicated 
and T2DM ECFC groups when measured acutely.  These observations suggest that 
differences in network structure may not be attributable to these phenotypes.  However, 
these unexpected results could be due to T2DM sample variability, method resolution, or 
a relatively low sample size.  Additionally, differences between population-based 
functional assessments versus single ECFC measurements may account for these 
findings.  For instance, KAV, a population-based analysis, identified differences between 
the clinical groups.  Subsequent ECFC studies (i.e. proliferation and motility) were at a 
single cell resolution.  However, as discussed above, single cell phenotypes correlated 
with measures of network formation.  Therefore, subtle alterations in single ECFC function 
may impact overall cell coordination required for optimal network formation.  Future 
studies that correlate individual cell functions with population-based read-outs are 
predicted to reveal a better understanding of the complex process of vasculogenesis. 
 
Studies using primary human stem/progenitors generate clinically relevant data. However, 
human samples from heterogeneous sources introduce variability, which can be a barrier 
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in identifying differences between groups with small sample sizes.  Overall, greater 
variation was observed in T2DM samples; consistent with the hypothesis that ECFC 
samples from T2DM mothers are heterogeneous with varying functionality due to factors 
such as disease severity and therapeutics used during pregnancy [79,81].  Thus, more 
sensitive readouts are necessary to delineate meaningful differences in a disease with 
significant heterogeneity. 
 
Overall, novel microscopic approaches described here were optimized to provide greater 
mechanistic insight into the dynamic process of vasculogenesis.  KAV identified two 
phases of network formation and guided further mechanistic studies of proliferation and 
motility, which correlated with network structure parameters.  These correlations provide 
new insight into how neonatal ECFC vasculogenesis may be altered from intrauterine 
T2DM exposure.   Importantly, the methods outlined have broad implications beyond the 
scope reported here.  Implementation of these approaches will enhance mechanistic 
assessment and improve functional readouts of vasculogenesis in numerous cell types or 
disease states. 
 
Aim 3: To determine if increased Transgelin 1 expression in ECFCs from gestational 
diabetic pregnancies impairs vasculogenesis. 
 
Implications of Altered TAGLN in GDM-exposed ECFCs 
Transgelin was originally identified as smooth muscle cell-specific, but increasing 
evidence suggest that this family of proteins is expressed in a variety of cell types including 
mesenchymal cells, fibroblasts, and epithelial cells [90,100].  Using a broad microarray 
screen, elevated TAGLN was identified in ECFCs isolated from pregnancies complicated 
with GDM.  As a result of intrauterine GDM exposure, ECFCs exhibit impaired functional 
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abilities including resistance to hyperglycemia-induced senescence and decreased 
network formation in vitro [79,81].  Therefore, this study aimed to determine if elevated 
TAGLN expression in GDM-exposed fetal ECFCs contributed to observed impairments in 
ECFC migration and network formation in vitro. 
 
Recent published studies in the laboratory demonstrated that ECFCs from T2DM 
pregnancies have increased nuclear localization of the transcription factor, Mesenchyme 
Homeobox 2 (MEOX2), which was sufficient to increase ECFC migration and network 
formation [82].  Therefore, increased MEOX2 expression was speculated to be a 
compensatory mechanism by which fetal ECFCs from T2DM pregnancies maintain 
vascular function despite poor intrauterine environments.  The identification of a 
dysregulated molecular mechanism in T2DM-exposed ECFCs prompted additional 
studies to identify specific molecular mechanisms altered by TAGLN expression in GDM-
exposed ECFCs. 
 
Molecular approaches were used to modify levels of TAGLN in ECFCs obtained from 
GDM and uncomplicated pregnancies prior to conducting functional assays.  Importantly, 
similar TAGLN expression was observed in ECFCs from uncomplicated pregnancies and 
GDM-exposed ECFCs following siRNA-mediated TAGLN knockdown.  Additionally, 
lentiviral-mediated TAGLN over-expression produced similar protein expression to levels 
observed endogenously in GDM-exposed ECFCs.  Therefore, TAGLN expression 
achieved in these studies was within a physiological range.  SiRNA-mediated reduction of 
TAGLN in GDM-exposed ECFCs increased the number of networks formed in Matrigel 
and the number of migrated cells in trans-well assays.  These data suggest that elevated 
TAGLN could be responsible for impaired network formation and migration in GDM-
exposed ECFCs.  This is supported by the observation that lentiviral-mediated over-
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expression of TAGLN in ECFCs from uncomplicated pregnancies reduced network 
number in Matrigel and the number of migrated cells in trans-well assays, suggesting that 
TAGLN alone was sufficient to impair network formation and migration.  In contrast to the 
protective effects of MEOX2 in T2DM-exposed ECFCs, elevated TAGLN expression in 
ECFCs from GDM pregnancies results in pathologic changes.  Therefore, TAGLN 
expression was not compensatory, but rather detrimental, as it reduced ECFC network 
formation and migration.  The difference between the consequences of elevated MEOX2 
and TAGLN in ECFCs could be due to the specific function of each protein, but differences 
could also be attributable to the severity and duration of the intrauterine diabetic 
microenvironment from which the cells were derived. 
 
TAGLN Regulates Cell Migration 
Two Transgelin genes, TAGLN and TAGLN2, are involved in the regulation of cell 
migration.  TAGLN2 expression in human umbilical vein endothelial cells decreases 
migration through a reduction in phosphorylation of MLC [111].  In HT1080 (human 
fibrosarcoma cell line) cells, TAGLN regulates MMP9, a key factor involved in the 
breakdown of extracellular matrix proteins to enhance migration [112].  Importantly, a high 
sequence conservation exists between all three Transgelin genes (Transgelin 1-3), 
including within the actin-binding domain.  Therefore, these pathways were tested to 
determine whether similar TAGLN-mediated mechanisms exist in ECFCS to regulate 
migration.  Although MMP9 is not detectable at the transcript level in ECFCs, MLC 
phosphorylation was increased in ECFC samples from GDM pregnancies.  Similarly, 
overexpression studies demonstrated that increased TAGLN was sufficient to enhance 
MLC phosphorylation in uncomplicated ECFC samples.  Although these results are not 
consistent with previous reports on TAGLN2 in human umbilical vein endothelial cells, the 
apparent discrepancy may be due to differences in cell types and Transgelin genes 
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studied.  In these overexpression studies, reduced phosphorylation of MLC, via Rho 
kinase inhibition, increased ECFC migration.  These data suggest that elevated MLC 
phosphorylation is pathologic, which may be secondary to altered actin cytoskeletal 
rearrangement. 
 
TAGLN Regulates ECFC Alignment Under Shear Stress 
Vascular endothelial cells comprising vessel walls are constantly exposed to 
hemodynamic forces.  Therefore, it is critical for endothelial cells to appropriately sense 
and respond to shear stress, most commonly laminar flow [148].  Endothelial cell 
alignment in the direction of laminar flow is a central feature of vascular homeostasis [149].  
Given that TAGLN is an actin binding protein involved in regulating cytoskeletal 
reorganization, we asked whether the increased TAGLN expression in GDM-exposed 
ECFCs was sufficient to impair ECFC alignment to laminar flow.  Initial studies 
demonstrated that overexpressing TAGLN altered ECFC alignment in basal as well as 
under flow conditions (Figure 39).  Alterations in alignment under basal conditions was 
surprising, as it wasn’t previously appreciated the extent to which ECFC organization can 
vary in static culture.  Next, GDM-exposed ECFCs with high endogenous TAGLN levels 
were assessed to identify if GDM exposure resulted in baseline impairment of cell 
alignment.  No differences in ECFC alignment were observed between samples from 
uncomplicated (UC) and GDM pregnancies following static culture (Figure 40).  However 
qualitative and quantitative differences between UC and GDM-exposed ECFC alignment 
were evident following seven hours of laminar flow exposure (Figure 40A-B).  Interestingly, 
the graphs depicting angle variance in the overexpression as well as the GDM 
experiments exhibit similar trends (Figures 39C and 40C).  Although differences in UC 
and GDM-exposed ECFC alignment in response to laminar flow were not statistically 
significant, the trend was similar to the malalignment observed in ECFCs overexpressing 
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TAGLN.  Previous functional assessments of GDM-exposed ECFCs required high sample 
numbers, likely due to disease heterogeneity and duration, which was evident in variability 
of GDM-exposed ECFC function measured in vitro.  Therefore, this preliminary study was 
likely underpowered to interrogate the question adequately.  Additional studies in which 
higher sample numbers are assessed will provide meaningful outcomes from which 
conclusions can be properly derived. 
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Future Directions 
 
Successful completion of the following experimental aims will provide further insight into 
genetic and mechanistic changes occurring in ECFCs following exposure to maternal 
diabetes in utero. 
 
1. To further evaluate how elevated TAGLN expression in GDM-exposed ECFCs 
impairs migration and network formation. 
 
Increasing Sample Size 
Although results from studies outlined in Aim 3 provide strong evidence that increased 
TAGLN expression in GDM-exposed ECFCs reduces migration and network formation, 
additional studies will strengthen the conclusions reported above.  Since assessment of 
GDM-exposed ECFC alignment to laminar flow was likely underpowered, additional 
studies testing greater sample numbers will be more convincing and enable formulation 
of stronger conclusions.  Simultaneous to testing additional samples in shear assays, KAV 
assays could be performed with GDM-exposed ECFC samples.  Several samples from 
T2DM pregnancies were assessed (Aim 2), however few samples from GDM pregnancies 
have been assessed in kinetic network formation assays.  Based on preliminary studies 
using three GDM samples (Figure 44), great heterogeneity in network formation kinetics 
was observed in GDM samples.  In our experience in the laboratory, heterogeneity is 
common in functional in vitro assessments of GDM-exposed ECFCs.  Therefore, testing 
a greater sample number will aid formulation of conclusions that pertain to a majority, if 
not all samples in that clinical group. 
 
 134 
Conducting Assessments on Matrigel 
ECFC gene expression, including TAGLN, is contingent on extracellular matrix 
composition (Figures 29 and 41).  Therefore, assessment of TAGLN expression on 
Matrigel will provide a more accurate measure of TAGLN levels, which would better inform 
network formation outcomes.  Therefore, TAGLN expression should be evaluated in 
additional ECFC samples on Matrigel, including ECFCs from uncomplicated and GDM 
pregnancies as well as those transfected with siRNA for knockdown studies and 
transduced with lentivirus for overexpression studies.  Similarly, trans-well studies outlined 
in Aim 3 results were conducted using type 1 collagen.  However, given that ECFC gene 
expression and function is altered on different extracellular matrices, it would be 
informative to conduct trans-well invasion assays in which trans-wells are coated with 
Matrigel instead of collagen, requiring ECFCs to “invade” the gel to migrate.  Given that 
differences in migration were not observed in GDM-exposed ECFCs plated on collagen 
(Figure 24), and previous assessments of GDM-exposed ECFCs reported altered 
performance under conditions of stress [81], perhaps conducting a different version of the 
trans-well assay using Matrigel would capture a new, biologically meaningful readout. 
 
Requirement of Actin Binding in TAGLN-mediated Effects 
Although it seems likely that TAGLN is altering ECFC cytoskeletal rearrangement, and 
thus migration, through binding to F-actin, it is unclear whether actin binding is required 
for TAGLN-mediated reductions in network formation, migration, and cell alignment.  To 
determine how disrupting actin binding impacts TAGLN-mediated dysfunction, site-
directed mutagenesis could be used to alter the actin-binding domain in the TAGLN 
sequence used for overexpression.  Based on foundational work in the literature 
characterizing TAGLN amino acids critical for actin binding [108], I propose three 
mutations, including two deletions and one in which 4 amino acids are altered (Delta 154-
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161, Delta 170-186, K154L/K155L/K160L/R161L).  I hypothesize that the TAGLN-
mediated effects on ECFC migration require actin binding, therefore overexpressing a 
mutant form of TAGLN unable to bind actin will not reduce ECFC migration or MLC 
phosphorylation.  Overexpression and MLC phosphorylation could be assessed by 
Western blotting and F-actin binding could be assessed by immunofluorescence and co-
immunoprecipitation assays. 
 
Centrifugation and flow cytometric assays were performed to assess total F-actin following 
TAGLN overexpression.  Using these approaches, no differences in total F-actin were 
identified, however the functional organization of F-actin into stress fibers was not 
assessed.  I hypothesize that TAGLN expression increases F-actin bundling, resulting in 
the formation of stress fibers.  To assess F-actin bundling, I propose to use fluorescence 
anisotropy as described by Koskinen et al. [150].  Briefly, inter-filament Förster resonance 
energy transfer (FRET) would be used to detect proximity of individual actin filaments, or 
actin bundling, following GFP labeling of actin monomers.  Increased bundling would result 
in increased local F-actin concentration and therefore, GFP-actin monomers.  Increased 
proximity of GFP-actin monomers would result in increased FRET, which would be 
quantitated to provide a measurable readout indicative of F-actin bundling. 
 
Assessing MLC Phosphorylation following TAGLN Knockdown 
Additional studies are needed to confirm MLC phosphorylation following siRNA-mediated 
TAGLN knockdown in GDM-exposed ECFCs.  Although differences in MLC 
phosphorylation were not observed under standard culture conditions following TAGLN 
reduction (Figure 32), these results are not conclusive.  As discussed in the Results, the 
timing of analysis may not have captured alterations in MLC phosphorylation.  Time course 
studies in which MLC phosphorylation was evaluated at multiple times spanning several 
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days would provide a more comprehensive analysis of the impact of knockdown duration 
on MLC phosphorylation.  Stress conditions that increase MLC phosphorylation, such as 
ionomycin treatment, could also be used as a terminal treatment to increase basal levels 
of MLC phosphorylation, resulting in a readout of greater differences in MLC 
phosphorylation following TAGLN knockdown.  Finally, knockdown of TAGLN was not 
complete, making it possible that residual TAGLN obscured detection of this phenotype.  
A CRISPR/Cas method to genetically delete TAGLN could be used to explore this 
possibility in the future.  Although it is also important to consider the possibility that TAGLN 
knockdown may not alter MLC phosphorylation due to activation of a compensatory 
mechanism in GDM-exposed ECFCs, which could be explored in future studies following 
the outcome of the additional analyses outlined above. 
 
2. To determine if TAGLN expression is regulated by methylation. 
 
Our data demonstrate that increased TAGLN expression in GDM-exposed ECFCs results 
in substantial functional deficits.  Our previous focus was on identifying the downstream 
consequences of increased TAGLN expression in ECFCs.  Future studies are necessary 
to dissect molecular mechanisms that promote increased TAGLN expression in order to 
discover potential therapeutics to overcome these changes.  To accomplish this goal, it is 
imperative to understand how TAGLN expression is regulated.   
 
In the Haneline laboratory, an RNA microarray (Affymetrix GeneChip) and a DNA 
methylation array (Illumina Infinium 450K) were conducted to identify differential gene 
expression and methylation between ECFCs isolated from uncomplicated pregnancies 
and those complicated by T2DM or GDM.  An inverse correlation was identified between 
DNA methylation in the TAGLN gene promoter region and TAGLN gene expression (r =-
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0.72, p=0.02, FDR=0.28, Emily Blue, unpublished data).  These data suggest that TAGLN 
expression in ECFCs may be regulated at the epigenetic level by DNA methylation, similar 
to recent published studies by Dr. Blue for placenta-specific 8 (PLAC8) [83].  Therefore, I 
hypothesize that decreased methylation in the TAGLN promoter region in GDM-exposed 
ECFCs leads to increased TAGLN gene expression.  To test this hypothesis, I would 
assess methylation status of the 10 CpG sites in the TAGLN promoter identified in the 
methylation array in ECFCs from uncomplicated and GDM pregnancies.  Confirmation of 
differential methylation in the TAGLN promoter would further support the hypothesis that 
intrauterine exposure to GDM induces epigenetic alterations in neonatal ECFCs that 
modify gene expression leading to altered ECFC function. 
 
3. Explore the mechanism(s) responsible for increased Notch signaling in GDM-
exposed ECFCs and determine whether altered Notch signaling impairs ECFC 
vasculogenesis. 
 
Diabetes Alters Notch and VEGF Signaling: Rationale for Targeted, Mechanistic Studies 
in GDM-exposed ECFCs 
Development of endothelial dysfunction resulting from diabetes mellitus is complex.  
Therefore, the molecular mechanisms underlying vascular disease progression are not 
fully understood [151].  One mechanism previously identified involved peroxisome 
proliferator-activated receptor-gamma co-activator 1 alpha (PGC-1α), a transcriptional co-
activator involved in regulation of energy metabolism.  In rodents and humans with 
diabetes mellitus, PGC-1α was elevated in endothelial cells and caused impairment of 
migration in vitro and vasculogenesis in vivo.  Importantly, the mechanisms responsible 
for these pathologic phenotypes were altered PGC-1α-induced Rac/Akt/eNOS signaling 
and Notch signaling [152].  Additional studies reported a deleterious effect of diabetes on 
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Notch activation contributing to abnormal vasculogenesis [153–155].  For example, in 
aortic endothelial cells obtained from streptozotocin-induced diabetic mice, cell migration, 
proliferation, and sprouting were rescued through inhibition of Notch signaling in vitro 
[153].  Moreover, inhibition of Notch signaling combined with VEGF stimulation in the hind 
limb ischemia model increased blood vessel density and perfusion in diabetic mice in vivo 
[153].  Additionally, in a spheroid model of endothelial cells on smooth muscle cell 
monolayers, high glucose treatment increased sprouting and branching and resulted in an 
increased number of tubes with small diameters.  However, the small tubes formed in high 
glucose conditions regressed and eventually disconnected [6].  The high glucose 
treatment induced JAGGED1 and suppressed NOTCH1 in this model.  Therefore, not only 
is Notch signaling up-regulated in endothelial cells from diabetic animals and humans, but 
Notch activation results in impairment of vasculogenesis. 
 
In addition to Notch signaling, VEGF signaling is also critical during vasculogenesis [4].  
VEGF regulates cellular processes primarily through ligand binding at surface receptors 
and subsequent signal transduction and activation of intracellular pathways.  Therefore, it 
is critical that vascular cells, such as endothelial cells, receive and respond appropriately 
to the external stimuli.  Diabetic patients exhibit VEGF resistance, in which reduced 
signaling occurs despite normal, or even elevated VEGF ligand expression [156].  
Specifically, diabetic patients have elevated levels of soluble VEGF, but no concomitant 
increase in VEGFR expression in the myocardium.  In fact, VEGFR1 and VEGFR2 levels 
were decreased in the samples from diabetic patients compared to samples from non-
diabetic patients.  Although these studies were carried out in cardiomyocytes and not 
endothelial cells, the impact of the diabetic environment on VEGF signaling is an important 
component to vascular health.  Our recent studies indicate that ECFCs isolated from the 
umbilical cord blood of diabetic mothers have altered network formation kinetics [133]. 
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Since the process of vasculogenesis is tightly regulated by crosstalk between the Notch 
and VEGF pathways, and Notch signaling is altered in response to high glucose 
[152,153,156], I hypothesize that these pathways are altered in diabetes-exposed ECFCs. 
 
Altered Notch Signaling in GDM-exposed ECFCs 
Previous gene expression studies conducted on ECFC samples from uncomplicated and 
diabetic pregnancies did not identify alterations in members of the Notch or VEGF 
signaling pathways.  However, those studies were conducted on a limited number of 
samples and ECFCs were plated on collagen, not Matrigel prior to RNA isolation.  ECFCs 
plated on collagen grow in a monolayer; whereas, ECFCs on Matrigel form complex 
network structures.  Additionally, different extracellular matrices engage and bind distinct 
integrins to induce specific intracellular interactions with cytoskeletal proteins and 
signaling cascades [157].  Therefore, preliminary studies were conducted to determine if 
the observed functional differences of ECFCs on Matrigel compared to collagen were 
accompanied by changes in Notch activation, including HEY1 and DLL4 expression.  
HEY1 is a transcriptional target of the Notch pathway that is commonly used as a measure 
of Notch pathway activation, and DLL4 is a membrane-bound ligand for multiple Notch 
receptors.  Analysis by qRT-PCR revealed a large increase in HEY1 and DLL4 on Matrigel 
compared to collagen in all samples tested (Figure 41).  Increases in both HEY1 and DLL4 
appear to be larger in the samples from T2DM and GDM pregnancies compared to the 
sample from an uncomplicated pregnancy (Figure 41-42).  These preliminary data suggest 
that the T2DM and GDM-exposed ECFCs may have an elevated response to a component 
in the Matrigel.  These results also emphasize the importance of assessing ECFC 
functionality in the context of network formation on Matrigel, as it likely results in the 
activation of different pathways.  Therefore, previous analyses of gene expression using 
samples plated on collagen may not reflect gene expression differences during ECFC 
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vasculogenesis.  In addition to following up on specific targets, such as Notch signaling 
ligands and receptors, it would also be worthwhile to repeat a broad gene expression 
survey using RNA samples from ECFCs on Matrigel. 
 
Differences in VEGFR2 Expression and Localization in GDM-exposed ECFCs 
While alterations in gene expression profiles on Matrigel are important, confirmatory 
protein analyses are challenging because the commonly used methods for collecting 
protein lysates are not feasible on Matrigel matrix due to the high protein concentration in 
the gel.  Therefore, to assess receptor and ligand expression at the protein level while 
ECFCs are actively forming networks, a protocol for immunofluorescence staining on 
Matrigel matrix was implemented in pilot studies.  This method is extremely powerful as it 
allows observation of changes in protein expression at a single cell level and identification 
of the location of those cells within the overall network structure.  Preliminary studies 
demonstrate differences in VEGFR2 expression between control and GDM-exposed 
ECFCs.  Two hours post-plating control ECFCs express predominantly VEGFR1 on the 
cell membrane in the node structures, and VEGFR2 on the tip, or extending cells (Figure 
43).  Conversely, the GDM-exposed ECFCs predominantly express VEGFR2 on the cell 
membrane of every cell in the network structure including the nodes (Figure 43).  
Increased VEGFR2 expression in the GDM-exposed ECFCs is consistent with increased 
Notch activity because VEGFR2 up-regulates DLL4, stimulating Notch activation [158] 
(Background Figure 2).  This observation provides insight into a possible mechanism by 
which GDM-exposed ECFCs form altered network structures. 
 
Overall, Notch and VEGF signaling play a critical role in vasculogenesis.  Importantly, 
hyperglycemia and diabetes mellitus alter activation of these signaling pathways, however 
no studies have investigated whether similar dysfunction occurs following intrauterine 
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diabetes mellitus exposure.  Based on these preliminary data, I hypothesize that 
intrauterine exposure to diabetes may be causing differential activation of these pathways 
during network formation.  These studies are critical to pursue, to evaluate a potential 
molecular mechanism underlying altered network formation kinetics identified by KAV 
(Figure 44).  Based on this contention, next steps would include broadly surveying Notch 
pathway components including Notch receptors (NOTCH1-4), Notch ligands (DLL1, DLL4, 
JAGGED1, JAGGED2), Notch transcriptional targets (Hey1, Hey1, Hes1), and VEGF 
receptors (VEGFR1-2) in ECFC patient samples from uncomplicated and GDM 
pregnancies plated on Matrigel.  Assessing expression of key components of the Notch 
and VEGF signaling pathways would provide evidence of Notch pathway activation and 
the specific ligands and receptors altered in GDM-exposed ECFCs.  Additionally, since 
conducting initial studies to assess expression of VEGFR1 and VEGFR2 on ECFCs in 
Matrigel, immunofluorescence techniques were optimized to enable large scale imaging 
of whole networks (Figure 11), and Tissue Cytometry (TC) was developed to quantitate 
localization of protein expression within network structures (Figure 12).  Therefore, to build 
on preliminary data shown in Figure 43, and to determine if GDM-exposed ECFCs exhibit 
increased VEGFR2 expression compared to uncomplicated controls, VEGFR1 and 
VEGFR2 expression should be analyzed in additional ECFC samples using optimized 
immunofluorescence techniques combined with TC analysis.  One of the strengths of TC 
is the ability to analyze expression and localization of multiple proteins simultaneously.  
Therefore, the staining strategy employed in the preliminary studies of VEGFR1 and 
VEGFR2 could be expanded to include co-staining with other Notch pathway receptors or 
ligands identified in the broad expression analysis on Matrigel.  Specifically, inclusion of a 
fluorescent probe for DLL4 in the VEGFR1 and VEGFR2 staining protocol would be 
informative since VEGFR2 up-regulates DLL4 and stimulates Notch activation.  An 
immunofluorescence approach might identify how crosstalk between the Notch and VEGF 
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pathways regulate ECFC vasculogenesis, and if those mechanisms are altered following 
intrauterine GDM exposure.  Upon identification of altered expression of specific Notch 
receptors or ligands in GDM-exposed ECFCs, targeted knockdown and lentiviral-
mediated overexpression approaches could be implemented to determine whether 
reductions in a specific protein are required to impair network formation or whether 
increased expression was sufficient to induce impaired network formation. 
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Closing Remarks on Broad Translational Implications of Research on ECFCs 
 
TAGLN: A Promising Target in Anti-Cancer Therapies 
Due to the unique proliferative and vasculogenic properties of ECFCs, increasing numbers 
of studies have explored potential applications of ECFCs for tissue regeneration, as 
biomarkers for vascular disease, and in anti-angiogenic cancer therapies [24,159].  During 
cancer progression, a common mechanism by which tumor suppressors achieve gene 
silencing is through CpG hyper-methylation in gene promoter regions [160,161].  
Therefore, to identify which genes are hyper-methylated in breast cancer tissues, Sayar 
et al. conducted a comprehensive microarray expression profiling analysis [162].  Based 
on results of the microarray analysis, TAGLN was identified as a primary target of DNA 
hyper-methylation.  Specifically, TAGLN expression was decreased in approximately 62% 
of breast tumors, compared to matched tissue [162].  Analysis of additional, public 
microarray methylation data (GSE201713 and GSE31979) identified TAGLN hyper-
methylation in approximately 63% of tumors tested [162].  Thus, methylation patterns in 
the TAGLN promoter region could serve as a diagnostic or prognostic biomarker in cancer. 
 
Decreased TAGLN has been identified in several different types of cancer, including 
breast, colon, lung, bladder, and prostate cancer [163–171].   Therefore, increasing 
studies are focused on targeting TAGLN in the development of anti-cancer therapies [172]. 
Specifically, actin stabilization and MMP9 regulation are two TAGLN-mediated 
mechanisms thought to be critical in cancer progression.  One of the common cancer cell 
phenotypes is actin disorganization.  Since TAGLN is an actin stabilizing protein, it acts 
like a tumor suppressor by protecting against cellular depolarization through induction of 
rigid actin stress fibers [172].  Secondly, TAGLN may act as a tumor suppressor through 
regulation of MMP9 expression [173,174].  MMP9 is a matrix metalloproteinase required 
 144 
for extracellular matrix degradation in the processes of cell migration and invasion [175].  
Therefore, in addition to the implications of TAGLN in diabetes, it may also be a useful 
target in the development of anti-cancer therapies. 
 
Translational Propositions: ECFCs as Therapeutic Agents 
Despite promising functional efficacy, isolation of sufficient cell numbers remains a 
prominent challenge in using ECFCs for angiogenic therapy [39].  To overcome this 
challenge, a protocol was developed to convert human induced pluripotent stem cells 
(hiPSCs) or embryonic stem cells (hESCs) into cord-blood-like ECFCs [135].  Importantly, 
the cord-blood-like cells express a stable endothelial phenotype, exhibit high clonal 
proliferative potential, and form perfused vessels in ischemia reperfusion models.  
Successfully recapitulating the functional phenotypes critical to ECFC vascular formation 
and repair using hiPSCs provides a unique opportunity to obtain clinically relevant cell 
numbers for the development of angiogenic therapies. 
 
Complementary to efforts in obtaining sufficient ECFCs for therapeutic use, recent studies 
confirmed sufficient recovery of ECFCs from cryopreserved cell samples up to 21 years 
old, which is key for future feasibility of transplanting ECFCs clinically [176].  Although the 
ECFC colonies were smaller in size following many years of cryopreservation, these 
studies support regenerative medicine efforts using banked ECFC samples.  ECFC 
isolation protocols have even been established in different model systems, such as rat, to 
enable assessment of function resulting from different pathophysiological states 
[159,177].  In an acute kidney injury rat model, administration of rat pulmonary 
microvascular ECFCs was sufficient to reduce renal injury and increase recovery speed 
[159].  Interestingly, the microvascular ECFCs administered achieved renal protection 
despite ineffective homing to the site of ischemic injury in the kidney.  This finding suggests 
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that ECFCs may secrete factors that enhance recovery following ischemia through 
preservation of microvascular function in the damaged tissue. 
 
Utilizing Measurements of ECFC Function at Birth to Predict Future Disease Risk. 
In addition to therapeutic applications, ECFCs are also being explored for use as 
biomarkers of diseases, especially cardiovascular-related diseases [178,179].  Generally, 
endothelial cell populations are considered useful biomarkers for cardiovascular disease 
due to their role in maintaining homeostasis by modulating vascular integrity and blood 
fluidity [180,181].  Alvarado-Moreno et al. conducted a broad study in which they evaluated 
ECFC number, frequency, and functional phenotypes in the setting of venous 
thromboembolic disease (VTD).  They detected a higher number of ECFCs in patients 
with VTD, and the ECFCs isolated from those patients had increased production of free 
radicals, reactive oxygen species (ROS), and inflammatory mediators such as tumor 
necrosis factor alpha (TNF-) and interferon gamma (INF-) [179].  These functional 
deficits are like other previously identified characteristics of dysfunctional endothelium 
[182].  However, unlike differentiated endothelium, deficits in undifferentiated progenitor 
cell populations, like ECFCs, may aid in the understanding of how chronic diseases, like 
VTD, persist. 
 
In addition to biomarkers for adult cardiovascular diseases, ECFCs are good candidates 
for assessing disease risk in children.  The study of fetal progenitor cell populations that 
are enriched in umbilical cord blood provides a unique, translational research opportunity 
to understand the impact of suboptimal intrauterine environments, such as maternal 
diabetes mellitus, on the development of future offspring morbidities [37,79,183].  
Importantly, not all forms of maternal diabetes mellitus, whether acquired prior to or during 
pregnancy, are equivalent. By obtaining pertinent patient data from individuals with a 
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variety of clinical backgrounds (i.e. HgA1C values, medications, etc.), a more 
comprehensive understanding of how disease management impacts fetal development 
can be achieved. 
 
In vitro studies of ECFC function indicated that exposure to hyperglycemia impaired the 
ability of ECFCs to undergo vasculogenesis [79].  However, since both the duration of 
diabetes exposure and the severity of hyperglycemia are different in GDM and T2DM, it 
is not surprising that these conditions result in different health outcomes.  Therefore, it is 
important for future studies to assess pre-gestational (T2DM) and gestational (GDM) 
diabetic pregnancies.  Currently limited clinical readouts are available to identify children 
at greatest risk of developing complications later in life following intrauterine T2DM and 
GDM exposure.  Therefore, if a mechanism was identified to link severity of intrauterine 
diabetic exposure with development of chronic vascular complications, new preventative 
strategies aimed at delaying or decreasing disease progression would be possible.  
Ultimately, longitudinal studies in which long-term health outcomes are assessed following 
intrauterine diabetes exposure would provide important validation for in vitro measures 
acquired at birth. 
 
Although these studies provide novel insights into ECFC vasculogenesis, additional 
studies are needed to determine the accuracy with which the in vitro assays recapitulate 
functional deficits in vivo.  Confirming long-term ECFC dysfunction resulting from 
developmental exposure to maternal diabetes would provide a strong link between 
progenitor cell dysfunction and subsequent development of vascular complications.  
Overall, ECFCs could be useful candidates for future preventative therapies.  The 
development of a useful, non-invasive platform for assessing severity of exposure at the 
time of birth would increase the accuracy of health assessments to enable more informed 
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predictions of long-term health outcomes.  Importantly, an in vitro platform assessing 
vascular cell function could be applied to evaluate health risk following exposure to a 
variety of abnormal gestational environments. 
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Figures (41-44) 
Figure 41. Enhanced Expression of Hey1 and DLL4 on Matrigel 
 
 
 
Graphs representing HEY1 and DLL4 mRNA expression in individual ECFC samples 
plated on collagen (black) and Matrigel matrix (gray).  All values are relative to the 
uncomplicated ECFC sample (Control) value on collagen following normalization with 
HPRT. (n=1)  
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Figure 42. Notch Signaling may be Increased in GDM-exposed ECFCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
HEY1 (A) and DLL4 (B) mRNA were measured in individual ECFC samples isolated from 
Matrigel matrix during network formation. Values were normalized to HPRT and are shown 
relative to uncomplicated ECFC expression levels (Control).  (n=1)  
A B 
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Figure 43. VEGFR2 Expression may be Altered in GDM-exposed ECFCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immunofluorescence images illustrating expression of VEGFR1 and VEGFR2 in 
uncomplicated (UC) and GDM-exposed ECFCS plated on Matrigel matrix for two hours.  
Nuclei are shown in blue, VEGFR1 in green, and VEGFR2 in red. Asterisks (*) indicate 
staining in the Golgi apparatus while arrowheads indicate tip cells and arrows mark the 
nodes.  Scale bars represent 40 μm.  
 
* 
* 
* 
* 
UC GDM 
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Figure 44. Preliminary Kinetic Analysis of GDM-exposed ECFCs 
 
 
Representative average trace graphs of the number of closed networks over 24 hours.  
Images were acquired in 15 minute intervals, combined into video and analyzed by Kinetic 
Analysis of Vasculogenesis (KAV) software.  The color-coded key identifies the individual 
cell samples used in three separate experiments (n=3).
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APPENDIX A: Protocol for Analyzing Immunofluorescence Mitotic Index Images 
 
1) Open FIJI 
2) Open Image Files  
a. ImportBioformats  
b. Check “Open All Series” 
3) Create Maximum Intensity Projection Images 
a. ImageStackZ projection 
b. Dropdown (Max Intensity) 
4) Adjust brightness and contrast in all open images at once 
a. ImageAdjust Brightness Contrast 
b. Click Set “Prop to all” 
5) Save versions of all files at this point—label MIPs 
6) View all images at once 
a. WindowTile 
7) Open Cell Counter  
a. PluginsAnalyzeCell Counter 
8) Open ROI Manager 
a. AnalyzeToolsROI Manager 
b. Click polygon tool in main FIJI menu 
c. Use “Add,” “Show All,” and “Labels” in the ROI manager window to add 
ROIs, see all ROIs, and label individual ROIs within an image 
9) Identify Nodes, outline with ROI (Best to do one image at a time) 
10) Area Measurements 
a. AnalyzeSet Measurements Check Area 
b. Select area on image and click Ctrl+M to get area in data table 
c. Record measurements in an excel data table 
11) Count nuclei/node, mitotic cells/node, and tubular mitotic cells with Cell counter 
and record in excel data table.  
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APPENDIX B: Protocol for Processing Fluorescence Images in FIJI (ImageJ) for 
TrackMate 
 
Opening a File: 
Open image in FIJI (Image J) by clicking File  Open or by dragging file to gray bar at 
base of FIJI program. 
 
Making a Selection: 
Use square or circle tool (2nd from left) to make selection around region or entire well.  
You can hold ‘Shift’ while dragging the selection tools to make a perfect square or circle.  
The white anchor points on the selection can be dragged to make the region 
larger/smaller. 
 
Manage Selections: 
 Analyze  Tools  ROI Manager 
You can use the ROI manager to save selections (size and shape). 
‘Add’: Adds a selection to the manager that you have just drawn on the image. 
‘More’: You can save your ROIs and use for future image analysis 
 
Crop: 
Once your selection is the correct size and is in the correct location you can crop. 
 Image Crop 
**However, for circles you will still have the original image in the corners after cropping. 
 EditClear Outside 
This will delete any information outside of the selection, and should default to black. 
 
Background Subtract: 
Process Subtract Background 
This is useful for cleaning up fluorescent images. 
 
Removing ROI: 
Click outside the region of the ROI to remove.  If that doesn’t work, can do 
ImageOverlayHide Overlay 
 
Removing circle for TrackMate Spot analysis: 
After cropping, clearing the outside, and the background subtract, you will still have a 
circle outline that will get picked up through the Trackmate analysis.  To get rid of that 
just create a smaller circle ROI that excludes just that line.  Use the techniques/tools 
described in “Making a Selection” above.  
 Then repeat: EditClear Outside 
This will delete any information outside of the selection, and should default to black. 
Adjust brightness and contrast as needed. 
 ImageAdjustBrightness/Contrast 
 
Open TrackMate: 
PluginsTrackingTrackMate 
New Screen should pop up that is labeled “TrackMate v2.0.4” or whichever version you 
are using.  Click “Next”.   
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For image analysis the following settings were used, however these may need to be 
adjusted based on image size and quality: 
DOG 
Average spot size 25 
Threshold 2 
Check ‘Use average threshold box’ 
Linking distances: 50, 90, 4 
Frame depth: 20  
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APPENDIX C: Protocol for Overlapping Separate Images in Photoshop 
 
1) Open the two images you wish to overlap in Photoshop (Image A and Image B) 
2) Select the frame of the image you wish to transfer (Image B) 
3) Type Ctrl+A to select the entire image 
4) Copy and Paste that image into the frame of the second image (Image A) 
5) With the new layer (Image B) selected in the Layers menu, click the arrow for the 
dropdown menu and select ‘Difference’  
6) This should overlap the two photos.   
 
*You can adjust the levels prior to overlapping the images if necessary.  To do that, click 
on the ‘IMAGE’ tab at the top of the screen.  Then select ‘Adjustments’ and then ‘Levels’. 
 
 
  
A B 
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APPENDIX D: Protocol for Merging Images in Photoshop 
 
Select 
FileAutomatePhotomerge 
Make sure all settings in the 
Photomerge screen match the 
settings outlined in yellow (right). 
Select Browse (red arrow) 
 
Highlight all images you would 
like to merge by holding down 
Shift (images in series) or Ctrl (images not in series) and click Open. 
 
The names of the images you 
selected should appear in the 
white box on the Photomerge 
screen. 
Click OK. 
Photoshop will attempt to 
merge all of the selected 
images together, hopefully 
resulting in one completely 
photomerged image.  
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Protocol for Merging Images in Photoshop continued 
 
If the photomerge is incomplete, select and 
drag the different layers so that they overlap 
and form one completely photomerged 
image.  
 
Select the layer(s) you wish to move (hold 
Shift or Ctrl to select multiple) and then select 
the black arrow tool from the tool window to 
move the images within the canvas. 
 
Sometimes altering the Opacity in the ‘Layers’ window is helpful when 
aligning the images. 
To create a larger canvas (work space) select Click ImageCanvas Size 
to make adjustments as needed. 
  
Layer
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Protocol for Merging Images in Photoshop continued 
 
Once the photomerge is complete, Click LayerFlatten Image 
Once the image is flattened Click FileSave As 
Label the merged image and under Save Options select “As a Copy” and Format as 
“JPEG”  
Click Save 
 
In the JPEG Options window 
under Image Options make 
sure the Quality is set to 8 / 
High and the Format is set at 
Baseline (“Standard”).  Click 
the Preview box and then click 
OK. 
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Protocol for Merging Images in Photoshop continued 
 
If the file size is too large to open in 
Image J, etc. you can adjust the image 
size by clicking on ImageImage size 
In the Image size window adjust the 
number of pixels for the width and the 
ratio for the height will automatically 
adjust.  Then click OK. 
 
For opening the Photomerged images in Image J to count closed networks for Matrigel 
typically 700 pixels (width) is a good size to use.  
 161 
APPENDIX E: Protocol for Automated Matrigel Counting Using ImageJ (Quick Version) 
 
1) Open FIJI (ImageJ) 
Creating ROI 
2) AnalyzeToolsROI Manager 
3) Drag saved ROIs (zipped folder) into the ‘Drag and Drop’ bar to open in Manager 
a. OR create a new ROI using the circle selection tool in the tool bar 
Opening and Converting Image 
4) Drag JPEG image into ‘Drag and Drop’ bar to open  
5) ImageType8 bit 
Running Plug-IN 
6) Click on ROI to view it on image 
7) Align ROI if needed 
8) EditClear Outside  
9) Plug-InsAnalyze Network 
Saving Files 
10) Two windows will open  
a. FileSave AsJPEG for the fused skeleton/mask image 
b. EditCopy data table into excel document 
c. FileSave AsOriginal image with ROI on it with _ROI added onto end of 
name 
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APPENDIX F: Protocol for Automated Network Analysis in FIJI (ImageJ) 
 
Open FIJI (Version from July 15, 2013) 
Drag the Plug-In (Analyze Networks 0.6.5) into the gray bar at the bottom of the software 
window. 
  
Then Click Save to add the Plug-In to the list. 
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Protocol for Automated Network Analysis in FIJI (Image J) continued 
 
Open the image you want to analyze in FIJI.  You can either click File->Open through 
the dropdown menu or you can drag the image file into the grey bar as in step 1. 
Create an ROI by first opening the ROI Manager.  Click on AnalyzeToolsROI 
Manager. 
 
 
Draw the shape on your image using the 
rectangle or circle tool. 
Click Add in the ROI manager window. 
(There is a quirk with the ROI manager—
sometimes you have to create a second ROI 
and Add it to the manager in order to click back 
and forth between the two in order to get the 
desired ROI to show up on your image). 
Once you have the ROI placed on your image in the desired location, go the Menu and 
Click Edit->Clear Outside.  This will delete the image outside of your ROI (useful for non 
rectangle shapes).  You can also go to ImageCrop if you are using a rectangular ROI. 
Then you are ready to run the Plug-In!  
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Protocol for Automated Network Analysis in FIJI (Image J) continued 
 
Go to the Menu Bar and click Plug-
InsAnalyze Networks. 
This will open up a window with options to 
alter the settings in the Plugin.  You can 
change the Thresholding method using the 
drop down arrow which is the most common 
adjustment.  Then Click OK. 
Once the Plug-In has finished the analysis, 
two windows will pop up. 
1) Data Table with values 
2) Image of the skeleton and mask 
On the Data Table, go to EditCut and then 
paste those values into an excel spreadsheet. 
Save the skeleton/mask image as  a TIFF.  
File Save AsTIFF 
I typically save the 
corresponding images in the 
correct subfolders. 
Save the cropped image 
(that you used the ROI to 
create) by going to 
FileSave AsTIFF also in 
the matching subfolder. 
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